<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002256924
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Nilo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NILOTINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2673.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Nilo is<br />Nilo is a medicine containing an active substance called Nilotinib.<br />What Nilo is used for<br />Nilo is used to treat a type of leukaemia called Philadelphia chromosome positive chronic myeloid leukaemia (Ph-positive CML). CML is a cancer of the blood which makes the body produce too many abnormal white blood cells.<br />Nilo is used in adult and paediatric patients with newly diagnosed CML or used in adult and paediatric patients with CML who are no longer benefiting from previous treatment including imatinib or who experienced serious side effects with previous treatment and are not able to continue taking it.<br />How Nilo works<br />In patients with CML, a change in DNA (genetic material) triggers a signal that tells the body to produce abnormal white blood cells. Nilo blocks this signal, and thus stops the production of these cells.<br />Monitoring during Nilo treatment<br />Regular tests, including blood tests, will be performed during treatment. These tests will monitor:<br />- the amount of blood cells (white blood cells, red blood cells and platelets) in the body to see how Nilo is tolerated.<br />- pancreas and liver function in the body to see how Nilo is tolerated.<br />- the electrolytes in the body (potassium, magnesium). These are important in the functioning of the heart.<br />- the level of sugar and fats in the blood.<br />The heart rate will also be checked using a machine that measures electrical activity of the heart (a test called an &ldquo;ECG&rdquo;).<br />Your doctor will regularly evaluate your treatment and decide whether you should continue to take Nilo.</p><p>If you are told to discontinue this medicine, your doctor will continue to monitor your CML and may tell you to re-start Nilo if your condition indicates that this is necessary.<br />If you have any questions about how Nilo works or why it has been prescribed for you or your child, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>2. Before You Take Nilo<br />Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information contained in this leaflet.<br />Do not take Nilo<br />- if you are allergic to nilotinib or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, tell your doctor before taking Nilo.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Nilo:<br />- if you have suffered prior cardiovascular events such as a heart attack, chest pain (angina), problems with the blood supply to your brain (stroke) or problems with the blood flow to your leg (claudication) or if you have risk factors for cardiovascular disease such as high blood pressure (hypertension), diabetes or problems with the level of fats in your blood (lipid disorders).<br />- if you have a heart disorder, such as an abnormal electrical signal called &ldquo;prolongation of the QT interval&rdquo;.<br />- if you are being treated with medicines that lower your blood cholesterol (statins), or affect the heart beat (anti-arrhythmics) or the liver (see Other medicines and Tasigna).- if you suffer from lack of potassium or magnesium.<br />- if you have a liver or pancreas disorder.<br />- if you have symptoms such as easy bruising, feeling tired or short of breath or have experienced repeated infections.<br />- if you have had a surgical procedure involving the removal of the entire stomach (total gastrectomy).<br />- if you have ever had or might now have a hepatitis B infection. This is because Nilo could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.<br />If any of these apply to you or your child, tell your doctor. During treatment with Nilo</p><p>- if you faint (loss of consciousness) or have an irregular heart beat while taking this medicine, tell your doctor immediately as this may be a sign of a serious heart condition. Prolongation of the QT interval or an irregular heart beat may lead to sudden death. Uncommon cases of sudden death have been reported in patients taking Nilo.<br />- if you have sudden heart palpitations, severe muscle weakness or paralysis, seizures or sudden changes in your thinking or level of alertness, tell your doctor immediately as this may be a sign of a fast breakdown of cancer cells called tumour lysis syndrome. Rare cases of tumour lysis syndrome have been reported in patients treated with Nilo.<br />- if you develop chest pain or discomfort, numbness or weakness, problems with walking or with your speech, pain, discolouration or a cool feeling in a limb, tell your doctor immediately as this may be a sign of a cardiovascular event. Serious cardiovascular events including problems with the blood flow to the leg (peripheral arterial occlusive disease), ischaemic heart disease and problems with the blood supply to the brain (ischaemic cerebrovascular disease) have been reported in patients taking Nilo. Your doctor should assess the level of fats (lipids) and sugar in your blood before initiating treatment with Nilo and during treatment.<br />- if you develop swelling of the feet or hands, generalised swelling or rapid weight gain tell your doctor as these may be signs of severe fluid retention. Uncommon cases of severe fluid retention have been reported in patients treated with Nilo.<br />If you are the parent of a child who is being treated with Nilo, tell the doctor if any of the above conditions apply to your child.</p><p>Children and adolescents<br />Nilo is a treatment for children and adolescents with CML. There is no experience with the use of this medicine in children below 2 years of age. There is no experience with the use of Nilo in newly diagnosed children below 10 years of age and limited experience in patients below 6 years of age who are no longer benefiting from previous treatment for CML. The long-term effects of treating children with Nilo for long periods of time are not known.<br />Some children and adolescents taking Nilo may have slower than normal growth. The doctor will monitor growth at regular visits.<br />Other medicines and Nilo<br />Nilo may interfere with some other medicines.<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:<br />- anti-arrhythmics &ndash; used to treat irregular heart beat;<br />- chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin &ndash; medicines that may have an unwanted effect on the electrical activity of the heart;<br />- ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin &ndash; used to treat infections;<br />- ritonavir &ndash; a medicine from the class &ldquo; antiproteases&rdquo; used to treat HIV;<br />- carbamazepine, phenobarbital, phenytoin &ndash; used to treat epilepsy;<br />- rifampicin &ndash; used to treat tuberculosis;<br />- St. John&rsquo;s Wort &ndash; a herbal product used to treat depression and other conditions (also known as Hypericum perforatum);<br />- midazolam &ndash; used to relieve anxiety before surgery;<br />- alfentanil and fentanyl &ndash; used to treat pain and as a sedative before or during surgery or medical procedures;<br />- cyclosporine, sirolimus and tacrolimus &ndash; medicines that suppress the &ldquo;self-defence&rdquo; ability of the body and fight infections and are commonly used to prevent the rejection of transplanted organs such as the liver, heart and kidney;<br />- dihydroergotamine and ergotamine &ndash; used to treat dementia;<br />- lovastatin, simvastatin &ndash; used to treat high level of fats in blood;<br />- warfarin &ndash; used to treat blood coagulation disorders (such as blood clots or thromboses);<br />- astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine).<br />These medicines should be avoided during your treatment with Nilo. If you are taking any of these,</p><p>your doctor might prescribe other alternative medicines.<br />If you are taking a statin (a type of medicine to lower your blood cholesterol), talk to your doctor or pharmacist. If used with certain statins, Tasigna may increase the risk of statin-related muscle problems, which on rare occasions can lead to serious muscle breakdown (rhabdomyolysis) resulting in kidney damage.<br />In addition, tell your doctor or pharmacist before taking Nilo if you are taking any antacids, which are medicines against heartburn.<br />These medicines need to be taken separately from Nilo:<br />- H2 blockers, which decrease the production of acid in the stomach. H2 blockers should be taken approximately 10 hours before and approximately 2 hours after you take Nilo;<br />- antacids such as those containing aluminium hydroxide, magnesium hydroxide and simethicone, which neutralise high acidity in the stomach. These antacids should be taken approximately 2 hours before or approximately 2 hours after you take Nilo.<br />You should also tell your doctor if you are already taking Nilo and you are prescribed a new medicine that you have not taken previously during Nilo treatment.<br />Nilo with food and drink<br />Do not take Nilo with food. Food may enhance the absorption of Nilo and therefore increase the amount of Nilo in the blood, possibly to a harmful level. Do not drink grapefruit juice or eat grapefruit. It may increase the amount of Nilo in the blood, possibly to a harmful level.<br />Pregnancy and breast-feeding<br />- Nilo is not recommended during pregnancy unless clearly necessary. If you are pregnant or think that you may be, tell your doctor who will discuss with you whether you can take this medicine during your pregnancy.<br />- Women who might get pregnant are advised to use highly effective contraception during treatment and for up to two weeks after ending treatment.<br />- Breast-feeding is not recommended during treatment with Nilo and for two weeks after the last dose. Tell your doctor if you are breast-feeding.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Driving and using machines<br />If you experience side effects (such as dizziness or visual disorders) with a potential impact on the ability to safely drive or use any tools or machines after taking this medicine, you should refrain from these activities until the effect has disappeared.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>3. How to take Nilo<br />Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />How much Nilo to take<br />Use in adults<br />- The recommended dose is 600 mg per day. This dose is achieved by taking two hard capsules of 150 mg twice a day<br />- The recommended dose is 800 mg per day. This dose is achieved by taking two hard capsules of 200 mg twice a day<br />Use in children and adolescents<br />- The dose given to your child will depend on your child&rsquo;s body weight and height. The doctor will calculate the correct dose to use and tell you which and how many capsules of Nilo to give to your child. The total daily dose you give to your child must not exceed 800 mg.<br />Older people (age 65 years and over)<br />Nilo can be used by people aged 65 years and over at the same dose as for other adults.<br />When to take Nilo<br />Take the hard capsules:<br />- twice a day (approximately every 12 hours);<br />- at least 2 hours after any food;<br />- then wait 1 hour before eating again.<br />If you have questions about when to take this medicine, talk to your doctor or pharmacist. Taking Nilo at the same time each day will help you remember when to take your hard capsules.<br />How to take Nilo<br />- Swallow the hard capsules whole with water.<br />- Do not take any food together with the hard capsules.<br />- Do not open the hard capsules unless you are unable to swallow them. If so, you may sprinkle the content of each hard capsule in one teaspoon of apple sauce and take it immediately. Do not use more than one teaspoon of apple sauce for each hard capsule and do not use any food other than apple sauce.<br />How long to take Nilo<br />Continue taking Nilo every day for as long as your doctor tells you. This is a long-term treatment.<br />Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. Your doctor may consider discontinuing your treatment with Nilo based on specific criteria. If you have questions about how long to take Nilo, talk to your doctor.</p><p>If you take more Nilo than you should<br />If you have taken more Nilo than you should have, or if someone else accidentally takes your hard capsules, contact a doctor or hospital for advice straight away. Show them the pack of hard capsules and this package leaflet. Medical treatment may be necessary.<br />If you forget to take Nilo<br />If you miss a dose, take your next dose as scheduled. Do not take a double dose to make up for a forgotten hard capsule.<br />If you stop taking Nilo<br />Do not stop taking this medicine unless your doctor tells you to do so. Stopping Nilo without your doctor&rsquo;s recommendation places you at risk for worsening of your disease which could have<br />life-threatening consequences. Be sure to discuss with your doctor, nurse, and/or pharmacist if you are considering stopping Nilo.<br />If your doctor recommends that you discontinue treatment with Nilo<br />Your doctor will regularly evaluate your treatment with a specific diagnostic test and decide whether you should continue to take this medicine. If you are told to discontinue Nilo, your doctor will continue to carefully monitor your CML before, during and after you have discontinued Nilo and may tell you to re-start Nilo if your condition indicates that this is necessary.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>4. Possible side effects<br />Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.<br />Nilo Capsules 150 mg<br />Some side effects could be serious<br />These side effects are very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people) or have been reported with frequency not known (cannot be estimated from the available data).<br />- rapid weight gain, swelling of hands, ankles, feet or face (signs of water retention)<br />- chest pain or discomfort, high blood pressure, irregular heart rhythm (fast or slow), palpitations (sensation of rapid heartbeat), fainting, blue discolouration of the lips, tongue or skin (signs of heart disorders)<br />- difficulty or painful breathing, cough, wheezing with or without fever, swelling of the feet or legs (signs of lung disorders)<br />- fever, easy bruising or unexplained bleeding, frequent infections, unexplained weakness (signs of blood disorders)<br />- weakness or paralysis of the limbs or face, difficulty speaking, severe headache, seeing, feeling or hearing things that are not there, loss of consciousness, confusion, disorientation, trembling, sensation of tingling, pain or numbness in fingers and toes (signs of nervous system disorders)<br />- abdominal pain, nausea, vomiting of blood, bloody stools, constipation, heartburn, stomach acid reflux, swollen abdomen (signs of gastrointestinal disorders)<br />- severe upper (middle or left) abdominal pain (sign of pancreatitis)<br />- yellow skin and eyes, nausea, loss of appetite, dark-coloured urine (signs of liver disorders)<br />- painful red lumps, skin pain, skin reddening, peeling or blisters (signs of skin disorders)<br />- pain in joints and muscles (signs of musculoskeletal pain)<br />- excessive thirst, high urine output, increased appetite with weight loss, tiredness (signs of high level of sugar in the blood)<br />- severe headache often accompanied by nausea, vomiting and sensitivity to light (signs of migraine)<br />- dizziness or spinning sensation (signs of vertigo)<br />- nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal results of blood tests (such as high levels of potassium, uric acid and phosphorous and low levels of calcium)<br />- pain, discomfort, weakness or cramping in the leg muscles, which may be due to decreased blood flow, ulcers on the legs or arms that heal slowly or not at all and noticeable changes in colour (blueness or paleness) or temperature (coolness) of the legs or arms, as these symptoms could be signs of artery blockage in the affected limb (leg or arm) and digits (toes or fingers)<br />- recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection).<br />- difficulty and pain when passing urine, abnormal urine colour (signs of kidney or urinary tract disorders)<br />- visual disturbances including blurred vision, perceived flashes of light, loss of vision, blood in eye, eye pain, redness, itching or irritation, dry eye, swelling or itching of the eyelids (signs of eye disorders)<br />Some side effects are very common (may affect more than 1 in 10 people)<br />- headache<br />- tiredness<br />- muscle pain<br />- itching, rash</p><p>- nausea<br />- hair loss<br />- musculoskeletal pain, muscle pain, pain in extremity, pain in joints, bone pain and spinal pain upon discontinuing treatment with Nilo<br />- slowing of growth in children and adolescents.<br />Some side effects are common (may affect up to 1 in 10 people)<br />- diarrhoea, vomiting, abdominal pain, stomach discomfort after meals, flatulence, swelling or bloating of the abdomen, constipation<br />- bone pain, pain in joints, muscle spasms, muscle weakness, pain in extremity, back pain, pain or discomfort in the side of the body<br />- upper respiratory tract infections<br />- dry skin, acne, wart, decreased skin sensitivity<br />- loss of appetite, disturbed sense of taste, weight increase<br />- insomnia, anxiety, depression<br />- night sweats, excessive sweating.<br />Some side effects are uncommon (may affect up to 1 in 100 people)<br />- generally feeling unwell<br />- painful and swollen joints (gout)<br />- inability to achieve or maintain an erection<br />- feeling body temperature change (including feeling hot, feeling cold)<br />- sensitive teeth.<br />The following other side effects have been reported with frequency not known (cannot be estimated from the available data)<br />- allergy (hypersensitivity to Nilo)<br />- bleeding, tender or enlarged gums<br />- skin cyst, thinning or thickening of the skin, thickening of the outermost layer of the skin, skin discolouration, hives, fungal infection of the feet<br />- thickened patches of red/silver skin (signs of psoriasis)<br />- haemorrhoids, anal abscess<br />- enterocolitis (inflammation of the bowel)<br />- feeling of hardening in the breasts, heavy periods, nipple swelling<br />- symptoms of restless legs syndrome (an irresistable urge to move a part of the body, usually the leg,accompanied by uncomfortable sensations).<br />- paralysis of any muscle of the face.<br />- memory loss, disturbed or depressed mood, lack of energy<br />- oral thrush<br />- increased skin sensitivity<br />- nose bleed<br />- dry mouth, sore throat, mouth sores<br />- frequent urine output<br />- herpes virus infection<br />- appetite disorder, weight decreased<br />- breast enlargement in men<br />- high blood level of alkaline phosphatase<br />- low blood level of potassium or calcium.<br />Nilo Capsules 200 mg<br />Some side effects could be serious<br />These side effects are very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people) or have been reported with frequency not known (cannot be estimated from the available data).<br />- rapid weight gain, swelling of hands, ankles, feet or face (signs of water retention)<br />- chest pain or discomfort, high blood pressure, irregular heart rhythm (fast or slow), palpitations (sensation of rapid heartbeat), fainting, blue discolouration of the lips, tongue or skin (signs of heart disorders)<br />- difficulty or painful breathing, cough, wheezing with or without fever, swelling of the feet or legs (signs of lungdisorders)<br />- fever, easy bruising or unexplained bleeding, frequent infections, unexplained weakness (signs of blood disorders)<br />- weakness or paralysis of the limbs or face, difficulty speaking, severe headache, seeing, feeling or hearing things that are not there, loss of consciousness, confusion, disorientation, trembling, sensation of tingling, pain or numbness in fingers and toes (signs of nervous system disorders)<br />- abdominal pain, nausea, vomiting of blood, bloody stools, constipation, heartburn, stomach acid reflux, swollen abdomen (signs of gastrointestinal disorders)<br />- severe upper (middle or left) abdominal pain (sign of pancreatitis)<br />- yellow skin and eyes, nausea, loss of appetite, dark-coloured urine (signs of liver disorders)<br />- painful red lumps, skin pain, skin reddening, peeling or blisters (signs of skin disorders)<br />- pain in joints and muscles (signs of musculoskeletal pain)</p><p>- excessive thirst, high urine output, increased appetite with weight loss, tiredness (signs of high level of sugar in the blood)<br />- severe headache often accompanied by nausea, vomiting and sensitivity to light (signs of migraine)<br />- dizziness or spinning sensation (signs of vertigo)<br />- nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal results of blood tests (such as high levels of potassium, uric acid and phosphorous and low levels of calcium)<br />- pain, discomfort, weakness or cramping in the leg muscles, which may be due to decreased blood flow, ulcers on the legs or arms that heal slowly or not at all and noticeable changes in colour (blueness or paleness) or temperature (coolness) of the legs or arms, as these symptoms could be signs of artery blockage in the affected limb (leg or arm) and digits (toes or fingers)<br />- recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection).<br />- weakness or paralysis of the limbs or face, difficulty speaking, severe headache, seeing, feeling or hearing things that are not there, changes in eyesight, loss of consciousness, confusion, disorientation, trembling, sensation of tingling, pain or numbness in fingers and toes (signs of nervous system disorders)<br />- thirst, dry skin, irritability, dark urine, decreased urine output, difficulty and pain when urinating, exaggerated sense of needing to urinate, blood in urine, abnormal urine colour (signs of kidney or urinary tract disorders)<br />- visual disturbances including blurred vision, double-vision or perceived flashes of light, decreased sharpness or loss of vision, blood in eye, increased sensitivity of the eyes to light, eye pain, redness, itching or irritation, dry eye, swelling or itching of the eyelids (signs of eye disorders)<br />- swelling and pain in one part of the body (signs of clotting within a vein)<br />- fast heartbeat, bulging eyes, weight loss, swelling at the front of the neck (signs of overactive thyroid gland)<br />- weight gain, tiredness, hair loss, muscle weakness, feeling cold (signs of underactive thyroid gland)<br />Some side effects are very common (may affect more than 1 in 10 people)<br />- headache<br />- tiredness<br />- muscle pain<br />- itching, rash</p><p>nausea<br />- hair loss<br />- musculoskeletal pain, muscle pain, pain in extremity, pain in joints, bone pain and spinal pain upon discontinuing treatment with Nilo<br />- slowing of growth in children and adolescents.<br />- diarrhoea<br />- headache<br />- tiredness, lack of energy<br />- muscle pain<br />- itching, rash<br />- nausea<br />- abdominal pain<br />- constipation<br />- vomiting<br />Some side effects are common (may affect up to 1 in 10 people)<br />- upper respiratory tract infections, pneumonia<br />- stomach discomfort after meals, flatulence, swelling or bloating of the abdomen<br />- bone pain, pain in joints, muscle spasms, muscle weakness<br />- pain including back pain, neck pain and pain in extremity, pain or discomfort in the side of the body<br />- dry skin, acne, wart, decreased skin sensitivity, hives<br />- loss of appetite, disturbed sense of taste, weight decrease or increase<br />- insomnia, depression, anxiety<br />- night sweats, excessive sweating<br />- generally feeling unwell<br />- voice disorder<br />- nose bleed<br />- frequent urine output.<br />Some side effects are uncommon (may affect up to 1 in 100 people)<br />- increased skin sensitivity<br />- dry mouth, sore throat, mouth sores<br />- breast pain<br />- painful and swollen joints (gout)<br />- increased appetite- attention disorder<br />- inability to achieve or maintain an erection<br />- breast enlargement in men<br />- flu-like symptoms<br />- bronchitis<br />- urinary tract infection<br />- herpes virus infection<br />- oral or vaginal thrush<br />- muscle and joint stiffness, joint swelling<br />- feeling body temperature change (including feeling hot, feeling cold)<br />- sensitive teeth<br />The following other side effects have been reported with frequency not known (cannot be estimated from the available data)<br />- allergy (hypersensitivity to Nilo)<br />- bleeding, tender or enlarged gums<br />- skin cyst, thinning or thickening of the skin, thickening of the outermost layer of the skin, skin discolouration, hives, fungal infection of the feet<br />- thickened patches of red/silver skin (signs of psoriasis)<br />- haemorrhoids, anal abscess<br />- enterocolitis (inflammation of the bowel)<br />- feeling of hardening in the breasts, heavy periods, nipple swelling<br />- symptoms of restless legs syndrome (an irresistable urge to move a part of the body, usually the leg, accompanied by uncomfortable sensations).<br />- paralysis of any muscle of the face.<br />- memory loss, disturbed mood<br />- oral warts<br />- reddening and/or swelling and possibly peeling on the palms and soles (so called hand-foot syndrome)<br />- increased sensitivity of the skin to light<br />- difficulty hearing, ear pain, noises (ringing) in the ears<br />- joint inflammation<br />- urinary incontinence<br />During Nilo treatment, you may also have some abnormal blood test results such as: (Nilo Capsules 150 mg and 200 mg)</p><p>- low level of blood cells (white cells, red cells, platelets) or haemoglobin<br />- increase in the number of platelets or white cells, or specific types of white cells (eosinophils) in the blood<br />- high blood level of lipase or amylase (pancreas function)<br />- high blood level of bilirubin or liver enzymes (liver function)<br />- low or high blood level of insulin (a hormone regulating blood sugar level)<br />- low or high level of sugar, or high level of fats (including cholesterol) in the blood<br />- high blood level of parathyroid hormone (a hormone regulating calcium and phosphorus level)<br />- change in blood proteins (low level of globulins or presence of paraprotein)<br />- high blood level of potassium, calcium, phosphorus or uric acid.<br />- high blood level of creatinine or urea (kidney function)<br />- high blood levels of enzymes (alkaline phosphatase, lactate dehydrogenase or creatine phosphokinase)<br />- low blood level of magnesium, potassium, sodium, calcium, or phosphorus<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)<br />Reporting of suspected adverse reactions<br />&bull; Saudi Arabia:<br />o Other GCC States:<br />Please contact the relevant competent authority.<br />The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999<br />o E-mail:npc.drug@sfda.gov.sa<br />o Website:https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30&deg;C.<br />&bull; Store in the original package in order to protect from moisture.<br />&bull; Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.<br />&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Nilo contains<br />The active substance is Nilotinib Hydrochloride dihydrate.<br />Nilo 150 mg:<br />Each Hard gelatin capsule contains Nilotinib Hydrochloride dihydrate equivalent to Nilo 150 mg.<br />The other ingredients are: colloidal silicon dioxide, dibasic calcium phosphate dihydrate, gelatin, iron oxide yellow, magnesium stearate, povidone, sodium lauryl sulfate, titanium dioxide and iron oxide red. The imprinting ink contains shellac, propylene glycol, strong ammonia solution, potassium hydroxide and iron oxide black.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nilo 200 mg:
Each Hard gelatin capsule contains Nilotinib Hydrochloride dihydrate equivalent to Nilo 200 mg.
The other ingredients are: colloidal silicon dioxide, dibasic calcium phosphate dihydrate, gelatin, iron oxide yellow, magnesium stearate, povidone, sodium lauryl sulfate and titanium dioxide.
The imprinting ink contains shellac, propylene glycol, strong ammonia solution and iron oxide red.
What Nilo looks like? Nilo Capsules 150 mg
Opaque Red cap & Opaque red body size '1' Hard gelatin capsules imprinted with 'H' on cap and '23' on body, filled with slightly yellow to yellowish granular powder.
Nilo Capsules 200 mg
Opaque yellow cap & yellow body size '0' Hard gelatin capsules imprinted with 'H' on cap and '24' on body, filled with slightly yellow to yellowish granular powder.
How supplied:
Nilo Capsules 150 mg and 200mg are supplied in Container pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacture: Hetero Labs Limited Unit V, India Marketing Authorisation Holder and Manufacturer Saudi Amarox Industrial Company<br />Aljameah Street, Malaz quarter,<br />Riyadh 11441, Saudi Arabia Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July, 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما ھو نیل و<br />یحتوي دواء نیلو على مادة فعالة تسمى نیلوتینیب.<br />دواعي استخدام نیل و<br />(Ph-positive CML). یستخدم نیلو لعلاج نوع من سرطان الدم یسمى سرطان الدم النخاعي المزمن الإیجابي كروموسوم فیلادلفیا<br />سرطان الدم النخاعي المزمن ھو سرطان یصیب الدم حیث یجعل الجسم ینتج الكثیر من خلایا الدم البیضاء غیر الطبیعیة.<br />یستخدم نیلو في المرضى البالغین والأطفال الذین تم تشخیصھم حدیثاً بسرطان الدم النخاعي المزمن. كما أنھ یستخدم في مرضى الأطفال<br />المصابین بسرطان الدم النخاعي المزمن الذین لم یعودوا یستفیدون من العلاج السابق بما في ذلك إیماتینیب أو الذین عانوا من آثار جانبیة<br />خطیرة مع العلاج السابق ولم یتمكنوا من الاستمرار في تناولھ.<br />كیف یعمل نیل و<br />في المرضى الذین یعانون من سرطان الدم النخاعي المزمن ، یؤدي التغییر في الحمض النووي (المادة الوراثیة) إلى إطلاق إشارة تخبر<br />الجسم بإنتاج خلایا دم بیضاء غیر طبیعیة. یعمل نیلو على حجب ھذه الإشارة ، وبالتالي یوقف إنتاج ھذه الخلایا.<br />المراقبة أثناء العلاج باستخدام نیلو<br />سیتم إجراء اختبارات منتظمة ، بما في ذلك اختبارات الدم ، أثناء العلاج. ستراقب ھذه الاختبارات:<br />- كمیة خلایا الدم (خلایا الدم البیضاء وخلایا الدم الحمراء والصفائح الدمویة) في الجسم لمعرفة مدى تحمل نیلو.<br />- وظائف البنكریاس والكبد في الجسم لمعرفة مدى تأثرھم بتناول نیلو.<br />- الشوارد في الجسم (البوتاسیوم ، المغنیسیوم). ھذه مھمة في عمل القلب.<br />- مستوى السكر والدھون في الدم.<br />&quot;ECG&quot; سیتم أیضًا فحص معدل ضربات القلب باستخدام جھاز یقیس النشاط الكھربائي للقلب (اختبار یسمى .(<br />سیقیم طبیبك علاجك بانتظام ویقرر ما إذا كان علیك الاستمرار في تناول نیلو .إذا طُلب منك التوقف عن استخدام ھذا الدواء ،<br />فسیستمر طبیبك في مراقبة ابیضاض الدم النقوي المزمن الخاص بك وقد یخبرك بإعادة بدء استخدام نیلو إذا كانت حالتك تشیر<br />إلى أن ھذا ضروري.<br />إذا كان لدیك أي أسئلة حول كیفیة عمل نیلو أو لماذا تم وصفھ لك أو لطفلك ، اسأل طبیبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا یجب علیك معرفتھ قبل القیام بتناول نیلو كبسول<br />اتبع تعلیمات الطبیب بدقة. قد تختلف عن المعلومات العامة الواردة في ھذه النشرة.<br />لا تستخدم نیلو كبسول<br />.( - إذا كنت تعاني من حساسیة تجاه نیلوتینیب أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم ٦<br />إذا كنت تعتقد أنك مصاب بالحساسیة ، أخبر طبیبك قبل تناول نیلو.<br />التحذیرات والاحتیاطات<br />تحدث مع طبیبك او الصیدلي قبل تناول نیلو:<br />- إذا كنت قد عانیت من اضطرابات قلبیة وعائیة سابقة مثل نوبة قلبیة ، أو ألم في الصدر (ذبحة صدریة) ، أو مشاكل في تدفق<br />الدم إلى دماغك (سكتة دماغیة) أو مشاكل في تدفق الدم إلى ساقك (العرج) أو إذا كان لدیك عوامل خطر للإصابة بأمراض<br />القلب والأوعیة الدمویة مثل ارتفاع ضغط الدم أو مرض السكري أو مشاكل في مستوى الدھون في الدم (اضطرابات الدھون).<br />&quot; QT - إذا كنت تعاني من اضطراب في القلب ، مثل إشارة كھربائیة غیر طبیعیة تسمى &quot;إطالة فترة .<br />- إذا كنت تعُالج بأدویة تخفض نسبة الكولیسترول في الدم (الستاتین) ، أو تؤثر على دقات القلب (مضادات عدم انتظام ضربات<br />القلب) أو الكبد (انظر الأدویة الأخرى وتناول نیلو كبسول).<br />- إذا كنت تعاني من نقص في البوتاسیوم أو الماغنیسیوم.<br />- إذا كنت تعاني من اضطراب في الكبد أو البنكریاس.<br />- إذا كانت لدیك أعراض مثل الكدمات بسھولة ، والشعور بالتعب أو ضیق التنفس أو الإصابة بعدوى متكررة.<br />- إذا كنت قد خضعت لعملیة جراحیة تنطوي على إزالة المعدة بالكامل (استئصال المعدة الكلي).<br />مرة B وذلك لأن نیلو قد یتسبب في تنشیط التھاب الكبد B. - إذا كنت قد أصبت أو قد تكون مصاباً الآن بعدوى التھاب الكبد<br />أخرى ، والذي یمكن أن یكون قاتلا في بعض الحالات. سیتم فحص المرضى بعنایة من قبل الطبیب بحثاً عن أعراض ھذه<br />العدوى قبل بدء العلاج.<br />- إذا كانت أي من ھذه تنطبق علیك أو على طفلك ، أخبر طبیبك أثناء العلاج بتناول نیل و.<br />- إذا أصبت بالإغماء (فقدان الوعي) أو كنت تعاني من عدم انتظام ضربات القلب أثناء تناول ھذا الدواء ، أخبر طبیبك على<br />أو عدم انتظام ضربات القلب إلى QT الفور لأن ھذا قد یكون علامة على وجود حالة قلبیة خطیرة. قد یؤدي إطالة فترة<br />الموت المفاجئ. تم الإبلاغ عن حالات غیر شائعة من الموت المفاجئ لدى المرضى الذین یتناولون نیلو.<br />- إذا كان لدیك خفقان قلب مفاجئ ، ضعف شدید في العضلات أو شلل ، نوبات صرع أو تغیرات مفاجئة في تفكیرك أو مستوى<br />الیقظة ، أخبر طبیبك على الفور لأن ھذه قد تكون علامة على انھیار سریع للخلایا السرطانیة تسمى متلازمة تحلل الورم. تم<br />الإبلاغ عن حالات نادرة لمتلازمة تحلل الورم لدى مرضى عولجوا باستخدام نیلو.<br />- إذا شعرت بألم أو انزعاج في الصدر ، أو خدر أو ضعف ، أو مشاكل في المشي أو الكلام ، أو ألم ، أو تغیر اللون ، أو شعور<br />بارد في أحد الأطراف ، أخبر طبیبك على الفور لأن ھذا قد یكون علامة على حدث قلبي وعائي. تم الإبلاغ عن أحداث<br />خطیرة في القلب والأوعیة الدمویة بما في ذلك مشاكل في تدفق الدم إلى الساق (مرض انسداد الشرایین المحیطیة) ، وأمراض<br />القلب الإقفاریة ومشاكل في تدفق الدم إلى الدماغ (مرض نقص ترویة الأوعیة الدمویة الدماغیة) في المرضى الذین یتناولون<br />نیلو. یجب أن یقوم طبیبك بتقییم مستوى الدھون والسكر في دمك قبل بدء العلاج باستخدام نیلو وأثناء العلاج.<br />- إذا أصبت بتورم في القدمین أو الیدین ، أو انتفاخ عام أو زیادة سریعة في الوزن ، أخبر طبیبك لأن ھذه قد تكون علامات على<br />احتباس السوائل الشدید. تم الإبلاغ عن حالات غیر شائعة من احتباس السوائل الشدید في المرضى الذین عولجوا باستخدام<br />نیلو.<br />إذا كنت والدًا لطفل یعالج باستخدا م نیلو ، أخبر الطبیب إذا كانت أي من الحالات المذكورة أعلاه تنطبق على طفلك.<br />الأطفال والمراھقون</p><p>نیلو ھو علاج للأطفال والمراھقین المصابین بسرطان الدم النخاعي المزمن. لا توجد خبرة عن استخدام ھذا الدواء لدى الأطفال الذین<br />تقل أعمارھم عن سنتین. لا توجد خبرة عن استخدام نیلو في الأطفال الذین تم تشخیصھم حدیثاً والذین تقل أعمارھم عن ۱۰ سنوات<br />CML وتتوافر خبرة محدودة عن المرضى الذین تقل أعمارھم عن ٦ سنوات والذین لم یعودوا یستفیدون من العلاج السابق لحالات .<br />الأعراض طویلة المدى لعلاج الأطفال باستخدام نیل و لفترات طویلة غیر معروفة.<br />قد یكون نمو بعض الأطفال والمراھقین الذین یتناولون نیلو أبطأ من النمو الطبیعي. سیقوم الطبیب بمراقبة النمو في زیارات منتظمة.<br />الأدویة الأخرى وتناول نیلو كبسول<br />قد یتداخل نیلو مع بعض الأدویة الأخرى.<br />أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدویة أخرى. وھذا یشمل على وجھ الخصوص:<br />- مضادات عدم انتظام ضربات القلب - تستخدم لعلاج عدم انتظام ضربات القلب.<br />- كلوروكین ، ھالوفانترین ، كلاریثرومیسین ، ھالوبیریدول ، میثادون ، موكسیفلوكساسین - أدویة قد یكون لھا تأثیر غیر<br />مرغوب فیھ على النشاط الكھربائي للقلب.<br />- كیتوكونازول ، إیتراكونازول ، فوریكونازول ، كلاریثرومیسین ، تیلیثرومیسین - تستخدم لعلاج الالتھابات.<br />- ریتونافیر - دواء من فئة &quot;مضادات البروتیاز&quot; المستخدمة لعلاج فیروس نقص المناعة البشریة ؛<br />- كاربامازیبین ، فینوباربیتال ، فینیتوین - یستعمل لعلاج الصرع.<br />- ریفامبیسین - یستعمل لعالج السل.<br />- نبتة سانت جون - منتج عشبي یستخدم لعلاج الاكتئاب والحالات الأخرى (المعروفة أیضًا باسم العرن المثقوب)<br />- میدازولام - یستخدم لتخفیف القلق قبل الجراحة.<br />- الفنتانیل وفنتانیل - یستخدمان لعلاج الآلام وكمسكن قبل أو أثناء الجراحة أو العلاج<br />- سیكلوسبورین ، سیرولیموس وتاكرولیموس - الأدویة التي تثبط قدرة الجسم على &quot;الدفاع عن النفس&quot; وتكافح العدوى وتستخدم<br />عادة لمنع رفض الأعضاء المزروعة مثل الكبد والقلب والكلى ؛<br />- ثنائي ھیدروإرغوتامین وإرغوتامین - یستخدمان لعلاج الخرف.<br />- لوفاستاتین ، سیمفاستاتین - یستعمل لمعالجة نسبة عالیة من الدھون في الدم.<br />- وارفارین - یستخدم لعلاج اضطرابات تخثر الدم (مثل جلطات الدم أو الجلطات).<br />- أستیمیزول ، تیرفینادین ، سیسابرید ، بیموزید ، كینیدین ، بیبریدیل أو قلویدات الإرغوت (إرغوتامین ، دیھیدروأرغوتامین).<br />یجب تجنب ھذه الأدویة أثناء علاجك باستخدام نیلو. إذا كنت تتناول أیاً من ھؤلاء ، وقد یصف لك طبیبك أدویة بدیلة أخرى.<br />إذا كنت تتناول الستاتین (نوع من الأدویة لخفض نسبة الكولیسترول في الدم) ، تحدث إلى طبیبك أو الصیدلي. إذا تم استخدامھ مع<br />بعض العقاقیر المخفضة للكولیسترول ، فقد یزید نیلو من خطر حدوث مشاكل عضلیة مرتبطة بالستاتین ، والتي یمكن أن تؤدي في<br />حالات نادرة إلى انھیار عضلي خطیر (انحلال الربیدات) مما یؤدي إلى تلف الكلى.<br />بالإضافة إلى ذلك ، أخبر طبیبك أو الصیدلي قبل تناول نیلو إذا كنت تتناول أي مضادات حموضة ، والتي ھي أدویة ضد الحموضة<br />المعویة.<br />ھذه الأدویة یجب أن تؤخذ منفصلة عن نیلو:<br />H والتي تقلل من إنتاج الحمض في المعدة. یجب تناول حاصرات 2 ، H - حاصرات 2 قبل حوالي ۱۰ ساعات وبعد حوالي<br />ساعتین من تناولك نیلو ؛<br />- مضادات الحموضة مثل تلك التي تحتوي على ھیدروكسید الألومنیوم وھیدروكسید المغنیسیوم والسیمیثیكون التي تعمل على<br />تحیید الحموضة العالیة في المعدة. یجب تناول مضادات الحموضة ھذه قبل ساعتین تقریباً أو بعد ساعتین تقریباً من تناول نیلو.<br />یجب علیك أیضًا إخبار طبیبك إذا كنت تتناول نیلو بالفعل وقد تم وصف دواء جدید لم تتناولھ من قبل أثناء علاج نیلو.<br />تناول نیلو مع الطعام والشراب<br />لا تتناول نیلو مع الطعام. قد یعزز الطعام من امتصاص النیلو وبالتالي یزید من كمیة نیلو في الدم ، وربما إلى مستوى ضار. لا تشرب<br />عصیر الجریب فروت ولا تأكل الجریب فروت. قد یزید من كمیة نیلو في الدم ، وربما إلى مستوى ضار.<br />الحمل والرضاعة<br />طبیبك الذي سیناقش معك ما إذا كان یمكنك تناول ھذا الدواء أثناء الحمل.<br />- ینُصح النساء اللواتي قد یصبحن حوامل باستخدام وسائل منع الحمل عالیة الفعالیة أثناء العلاج ولمدة تصل إلى أسبوعین بعد<br />إنھاء العلاج.<br />- لا ینصح بالرضاعة الطبیعیة أثناء العلاج باستخدام نیلو ولمدة أسبوعین بعد آخر جرعة. أخبر طبیبك إذا كنت مرضعة.<br />إذا كنت حاملا أو مرضعة ، تعتقدین أنك حامل أو تخططین لإنجاب طفل ، اسألي طبیبك أو الصیدلي للحصول على المشورة قبل تناول<br />ھذا الدواء.<br />القیادة واستخدام الآلات<br />إذا كنت تعاني من آثار جانبیة (مثل الدوخة أو اضطرابات بصریة) مع تأثیر محتمل على القدرة على القیادة بأمان أو استخدام أي أدوات<br />أو آلات بعد تناول ھذا الدواء ، یجب علیك الامتناع عن ھذه الأنشطة حتى یختفي التأثیر.<br />۳. طریقة استخدام نیلو كبسول<br />احرص دائمًا على تناول ھذا الدواء تمامًا كما أخبرك طبیبك أو الصیدلي. استشر طبیبك أو الصیدلي إذا لم تكن متأكدًا.<br />الجرعة التي ینبغي أن تتناولھا من نیلو كبسول<br />الاستخدام في البالغین<br />- الجرعة الموصى بھا ھي ٦۰۰ ملجرام في الیوم. یتم الحصول على ھذه الجرعة بتناول كبسولتین ۱٥۰ ملجرام مرتین في<br />الیوم.<br />- الجرعة الموصى بھا ھي ۸۰۰ ملجرام في الیوم، تتحقق ھذه الجرعة بتناول كبسولتین صلبتین ۲۰۰ ملجرام مرتین في الیوم.<br />الاستخدام في الأطفال والمراھقین<br />- ستعتمد الجرعة المعطاة لطفلك على وزن جسم طفلك وطولھ. سیحسب الطبیب الجرعة الصحیحة لاستخدامھا ویخبرك بتركیز<br />كبسولات نیلو التي یجب إعطاؤھا لطفلك وعدد كبسولاتھا. یجب ألا یتجاوز إجمالي الجرعة الیومیة التي تعطیھا لطفلك ۸۰۰<br />ملجرام.<br />كبار السن ( ٦٥ سنة فأكثر)<br />یمكن استخدام نیلو من قبل الأشخاص الذین تبلغ أعمارھم ٦٥ عامًا وأكثر بنفس الجرعة المستخدمة للبالغین.<br />موعد تتناول نیلو كبسول<br />تناول الكبسولات الصلبة:<br />- مرتین في الیوم (كل ۱۲ ساعة تقریبًا) ؛<br />- ساعتین على الأقل بعد تناول أي طعام ؛<br />- ثم انتظر لمدة ساعة قبل الأكل مرة أخرى.<br />إذا كانت لدیك أسئلة حول موعد تناول ھذا الدواء ، فتحدث إلى طبیبك أو الصیدلي. سیساعدك تناول نیلو في نفس الوقت كل یوم<br />على تذكر موعد تناول كبسولاتك الصلبة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كیفیة استخدام نیلو كبسو ل<br />- ابتلع الكبسولات الصلبة كاملة بالماء.<br />- لا تتناول أي طعام مع الكبسولات الصلبة.<br />- لا تفتح الكبسولات الصلبة إلا إذا كنت غیر قادر على ابتلاعھا. إذا كان الأمر كذلك ، یمكنك رش محتوى كل كبسولة صلبة في<br />ملعقة صغیرة من صلصة التفاح وتناولھا على الفور. لا تستخدم أكثر من ملعقة صغیرة من صلصة التفاح لكل كبسولة صلبة<br />ولا تستخدم أي طعام غیر صلصة التفاح.<br />مدة العلاج بتناول نیلو كبسول<br />استمر في تناول نیلو كل یوم لطالما أخبرك طبیبك. حیث یعتبر ھذا علاج طویل الأمد.<br />سیراقب طبیبك حالتك بانتظام للتحقق من أن العلاج لھ التأثیر المطلوب.</p><p>فتحدث إلى طبیب ك.<br />تناول جرعة زائدة من نیلو كبسو ل<br />إذا كنت قد تناولت جرعة زائدة من نیلو أكثر مما ینبغي ، أو إذا أخذ شخص آخر الدواء عن طریق الخطأ ، اتصل بالطبیب أو المستشفى<br />للحصول على المشورة على الفور. أظھر لھم علبة الكبسولات الصلبة وھذه النشرة. قد یكون العلاج الطبي ضروریاً.<br />إذا نسیت أن تتناول نیلو كبسو ل<br />إذا فاتتك جرعة ، تناول جرعتك التالیة كما ھو مقرر. لا تتناول جرعة مضاعفة لتعویض الجرعة المنسیة.<br />التوقف عن تتناول نیلو كبسول<br />لا تتوقف عن تناول ھذا الدواء ما لم یخبرك طبیبك بذلك.<br />إن إیقاف نیلو بدون توصیة طبیبك یعرضك لخطر تفاقم مرضك مما قد یكون لھ عواقب تھدد حیاتك. تأكد من مناقشة طبیبك و / أو<br />ممرضتك و / أو الصیدلي إذا كنت تفكر في إیقاف نیلو.<br />إذا أوصى طبیبك بالتوقف عن العلاج باستخدام نیل و<br />سیقوم طبیبك بتقییم علاجك بانتظام من خلال اختبار تشخیصي محدد ویقرر ما إذا كان یجب أن تستمر في تناول ھذا الدواء. إذا طُلب<br />منك التوقف عن استخدام نیلو ، فسیقوم طبیبك بذلك.<br />استمر في مراقبة سرطان الدم النخاعي المزمن بعنایة قبل وأثناء وبعد توقفك عن نیلو وقد یطلب منك إعادة استخدام نیلو إذا كانت حالتك<br />تشیر إلى أن ھذا ضروري.<br />إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء ، اسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة ، یمكن أن یسبب ھذا الدواء آثارًا جانبیة ، على الرغم من عدم حدوثھا لدى الجمیع. معظم الأعراض الجانبیة خفیفة<br />إلى معتدلة وتختفي بشكل عام بعد بضعة أیام إلى بضعة أسابیع من العلاج.<br />قد تكون بعض الأعراض الجانبیة خطیرة (نیلو كبسول ۱٥۰ ملجرا م و ۲۰۰ ملجرام).<br />ھذه الأعراض الجانبیة شائعة جدًا (قد تؤثر على أكثر من ۱ من كل ۱۰ أشخاص) ، شائعة (قد تؤثر على ما یصل إلى ۱ من كل ۱۰<br />أشخاص) ، غیر شائعة (قد تؤثر على ما یصل إلى ۱ من كل ۱۰۰ شخص) أو تم الإبلاغ عنھا بمعدلات غیر معروفة (لا یمكن تقدیرھا<br />من البیانات المتاحة).<br />- زیادة سریعة في الوزن ، تورم في الیدین ، الكاحلین ، القدمین أو الوجھ (علامات احتباس الماء).<br />- ألم أو انزعاج في الصدر ، ارتفاع ضغط الدم ، عدم انتظام ضربات القلب (سریع أو بطيء) ، خفقان (الإحساس بنبض قلب<br />سریع) ، إغماء ، تغیر لون الشفاه أو اللسان أو الجلد باللون الأزرق (علامات لاضطرابات في القلب) .<br />- صعوبة أو ألم في التنفس ، سعال ، صفیر عند التنفس مع أو بدون حمى ، تورم في القدمین أو الساقین (علامات لاضطرابات<br />في الرئة).<br />- سخونة ، كدمات سھلة أو نزیف غیر مبرر ، عدوى متكررة ، ضعف غیر مبرر (علامات لاضطرابات في الدم) .<br />- ضعف أو شلل في الأطراف أو الوجھ ، صعوبة في الكلام ، صداع شدید ، رؤیة ، شعور أو سماع أشیاء غیر موجودة ، فقدان<br />الوعي ، ارتباك ، ارتعاش ، إحساس بوخز ، ألم أو تنمیل في أصابع الیدین والقدمین (علامات) من اضطرابات الجھاز<br />العصبي).<br />- آلام في البطن ، غثیان ، قيء دموي ، براز دموي ، إمساك ، حرقة في المعدة ، ارتجاع حمض المعدة ، انتفاخ البطن<br />(علامات لاضطرابات معدیة معویة).<br />- آلام شدیدة في الجزء العلوي (الأوسط أو الأیسر) من البطن (علامة على التھاب البنكریاس).<br />- اصفرار الجلد والعینین ، غثیان ، فقدان الشھیة ، بول داكن اللون (علامات لاضطرابات الكبد) .<br />- كتل حمراء مؤلمة ، ألم جلدي ، احمرار في الجلد ، تقشر أو بثور (علامات لاضطرابات جلدیة) .<br />- ألم في المفاصل والعضلات (علامات لألم في الجھاز العضلي الھیكلي).<br />- العطش الشدید ، زیادة التبول ، زیادة الشھیة مع فقدان الوزن ، التعب (علامات ارتفاع نسبة السكر في الدم).<br />- صداع شدید یصاحبھ غثیان وقيء وحساسیة للضوء (علامات الصداع النصفي).<br />-<br />الدوخة أو الإحساس بالدوار (علامات الدوخة).<br />- الغثیان ، وضیق التنفس ، وعدم انتظام ضربات القلب ، وتغیم البول ، والتعب و / أوالشعور بعدم الراحة في المفاصل المرتبط<br />بنتائج غیر طبیعیة لاختبارات الدم (مثل ارتفاع مستویات البوتاسیوم وحمض الیوریك والفوسفور وانخفاض مستویات<br />الكالسیوم).<br />- ألم أو إزعاج أو ضعف أو تقلصات في عضلات الساق ، والتي قد تكون بسبب انخفاض تدفق الدم ، أو تقرحات في الساقین أو<br />الذراعین تلتئم ببطء أو لا تلتئم على الإطلاق وتغیرات ملحوظة في اللون (الزرقة أو الشحوب) أو درجة الحرارة (البرودة) في<br />الساقین أو الذراعین ، حیث یمكن أن تكون ھذه الأعراض علامات على انسداد الشریان في الطرف المصاب (الساق أو<br />الذراع) والأصابع (أصابع القدم أو الأصابع).<br />B عندما یكون لدیك التھاب الكبد B - تكرار (إعادة تنشیط) عدوى التھاب الكبد في الماضي (التھاب الكبد) .</p><p>نیلو كبسول ۱٥۰ ملجرام<br />- صعوبة وألم عند التبول ، لون بول غیر طبیعي (علامات على اضطرابات الكلى أو المسالك البولیة).<br />- اضطرابات بصریة بما في ذلك عدم وضوح الرؤیة ، ومضات من الضوء ، وفقدان الرؤیة ، ودم في العین ، وآلام في العین ،<br />واحمرار ، وحكة أو تھیج ، وجفاف العین ، وتورم أو حكة في الجفون (علامات لاضطرابات العین).<br />نیلو كبسول ۲۰۰ ملجرام<br />- ضعف أو شلل في الأطراف أو الوجھ ، صعوبة في الكلام ، صداع شدید ، رؤیة ، شعور أو سماع أشیاء غیر موجودة ،<br />تغیرات في البصر ، فقدان الوعي ، ارتباك ، ارتعاش ، إحساس بوخز ، ألم أو تنمیل في الأصابع وأصابع القدم (علامات<br />اضطرابات الجھاز العصبي).<br />- العطش ، وجفاف الجلد ، والتھیج ، والبول الداكن ، وانخفاض كمیة البول ، وصعوبة وألم عند التبول ، وإحساس مفرط<br />بالحاجة إلى التبول ، ودم في البول ، واضطراب في لون البول (علامات لاضطرابات الكلى أو المسالك البولیة) .<br />- اضطرابات بصریة بما في ذلك عدم وضوح الرؤیة ، ازدواج الرؤیة أو ومضات من الضوء ، انخفاض حدة أو فقدان الرؤیة ،<br />دم في العین ، زیادة حساسیة العین للضوء ، ألم في العین ، احمرار ، حكة أو تھیج ، جفاف العین ، تورم أو حكة من الجفون<br />(علامات لاضطرابات العین).<br />- تورم وألم في جزء واحد من الجسم (علامات تخثر في الورید).<br />- تسارع ضربات القلب ، جحوظ العینین ، فقدان الوزن ، انتفاخ في مقدمة العنق (علامات فرط نشاط الغدة الدرقیة) .<br />- زیادة الوزن ، التعب ، تساقط الشعر ، ضعف العضلات ، الشعور بالبرودة (علامات نقص نشاط الغدة الدرقیة).<br />بعض الأعراض الجانبیة شائعة جدًا (نیلو كبسول ۱٥۰ ملجرام و ۲۰۰ ملجرام) (قد تؤثر على أكثر من ۱ من كل ۱۰ أشخاص).<br />- صداع الراس<br />- التعب<br />- ألم عضلي<br />- حكة ، طفح جلدي<br />- غثیان<br />- تساقط الشعر<br />- آلام العضلات والعظام وآلام في الأطراف وآلام في المفاصل وآلام العظام والعمود الفقري عند التوقف عن العلاج باستخدام<br />نیلو<br />- تباطؤ النمو عند الأطفال والمراھقین.<br />نیلو كبسول ۲۰۰ ملجرام<br />- إسھال<br />- صداع الراس<br />- التعب وقلة المجھود<br />- ألم عضلي<br />- حكة ، طفح جلدي<br />- غثیان<br />- وجع بطن<br />- إمساك<br />- قيء</p><p>بعض الأعراض الجانبیة شائعة (قد تظھر لدى حتى ۱ من كل ۱۰ أشخاص).<br />نیلو كبسول ۱٥۰ ملجرام<br />- الإسھال والقيء وآلام البطن والمعدة بعد الوجبات وانتفاخ البطن والإمساك.<br />- آلام العظام ، آلام المفاصل ، تقلصات العضلات ، ضعف العضلات ، آلام الأطراف ، آلام الظھر ، ألم أو عدم راحة في جانب<br />الجسم<br />- التھابات الجھاز التنفسي العلوي<br />- جفاف الجلد ، حب الشباب ، البثور ، انخفاض حساسیة الجلد<br />- فقدان الشھیة ، اضطراب حاسة التذوق ، زیادة الوزن<br />- الأرق والقلق والاكتئاب<br />- تعرق لیلي ، تعرق شدید<br />نیلو كبسول ۲۰۰ ملجرام<br />- التھابات الجھاز التنفسي العلوي والالتھاب الرئوي<br />- انزعاج في المعدة بعد الوجبات ، انتفاخ البطن<br />- آلام العظام ، آلام المفاصل ، تقلصات العضلات ، ضعف العضلات<br />- آلام تشمل آلام الظھر والرقبة وآلام في الأطراف ، وألم أو انزعاج في جانب الجسم<br />- جفاف الجلد ، حب الشباب ، البثور ، انخفاض حساسیة الجلد ، الشرى<br />- فقدان الشھیة ، واضطراب حاسة التذوق ، ونقص الوزن أو زیادتھ<br />- الأرق والاكتئاب والقلق<br />- تعرق لیلي ، تعرق شدید<br />- الشعور بتوعك بشكل عام<br />- اضطراب الصوت<br />- نزیف بالأنف<br />- كثرة التبول.<br />بعض الأعراض الجانبیة غیر شائعة (قد تظھر لدى حتى ۱ من كل ۱۰۰ شخص).<br />نیلو كبسول ۱٥۰ ملجرام<br />- الشعور بتوعك بشكل عام.<br />- ألم وتورم المفاصل (النقرس).<br />- عدم القدرة على تحقیق الانتصاب أو الحفاظ علیھ.<br />- الشعور بتغیر درجة حرارة الجسم (بما في ذلك الشعور بالحرارة والبرودة).<br />- حساسیة الأسنان.<br />نیلو كبسول ۲۰۰ ملجرام<br />- زیادة حساسیة الجلد.<br />- جفاف الفم ، التھاب الحلق ، تقرحات الفم.<br />- ألم الثدي .<br />- ألم وتورم المفاصل (النقرس).<br />- زیادة الشھیة<br />- اضطراب الانتباه<br />- عدم القدرة على تحقیق الانتصاب أو الحفاظ علیھ<br />- تضخم الثدي عند الرجال<br />- باعراض تشبھ اعراض الانفلونزا<br />- التھاب شعبي<br />- التھاب المسالك البولی ة<br />- عدوى فیروس الھربس<br />- مرض القلاع الفموي أو المھبلي<br />- تصلب العضلات والمفاصل وتورم المفاصل</p><p>الشعور بتغیر درجة حرارة الجسم (بما في ذلك الشعور بالحرارة والبرودة).<br />- حساسیة الأسنان<br />تم الإبلاغ عن الأعراض الجانبیة الأخرى التالیة بمعدل غیر معروف لا یمكن الكشف عنھا معدل حدوثھا من البیانات المتاحة (نیلو<br />كبسول ۱٥۰ ملجرام و ۲۰۰ ملجرام)<br />- الحساسیة (فرط الحساسیة تجاه نیلو).<br />- نزیف أو ألم أو تضخم اللث ة<br />- تكیسات جلدیة ، ترقق أو سماكة الجلد ، سماكة الطبقة الخارجیة من الجلد ، تغیر لون الجلد ، خلایا ، عدوى فطریة في القدمین<br />- بقع سمیكة من الجلد الأحمر / الفضي (علامات الصدفیة).<br />- البواسیر ، خراج الشرج<br />- التھاب الأمعاء (التھاب الأمعاء).<br />- الشعور بتصلب في الثدیین ، غزارة الدورة الشھریة ، انتفاخ الحلمة<br />- أعراض متلازمة تململ الساقین (رغبة لا تقاوم لتحریك جزء من الجسم ، عادة الساق ، مصحوبة بأحاسیس غیر مریحة).<br />- شلل أي عضلة في الوجھ.<br />نیلو كبسول ۱٥۰ ملجرام<br />- فقدان الذاكرة ، مزاج مضطرب أو مكتئب ، قلة المجھود<br />- القلاع الفموي<br />- زیادة حساسیة الجلد<br />- نزیف بالأنف<br />- جفاف الفم ، التھاب الحلق ، تقرحات الفم<br />- كثرة التبول<br />- عدوى فیروس الھربس<br />- اضطراب الشھیة ، نقص الوزن<br />- تضخم الثدي عند الرجال<br />نیلو كبسول ۲۰۰ ملجرام<br />- فقدان الذاكرة ، اضطراب المزاج<br />- القلاع الفموي<br />- احمرار و / أو تورم وربما تقشر في الراحتین والأخمصین (ما یسمى بمتلازمة الید والقدم).<br />- زیادة حساسیة الجلد للضوء<br />- صعوبة في السمع ، ألم في الأذن ، ضوضاء (رنین) في الأذنی ن<br />- التھاب المفاصل<br />- سلس البول<br />أثناء العلاج باستخدام نیلو (نیلو كبسول ۱٥۰ ملجرام و ۲۰۰ ملجرام). ، قد یكون لدیك أیضًا بعض نتائج اختبارات الدم غیر<br />الطبیعیة مثل:<br />- انخفاض مستوى خلایا الدم (خلایا الدم البیضاء ، خلایا الدم الحمراء ، الصفائح الدمویة) أو الھیموجلوبین<br />- زیادة في عدد الصفائح الدمویة أو خلایا الدم البیضاء أو أنواع معینة من الخلایا البیضاء (الحمضات) في الدم.<br />- ارتفاع نسبة اللیباز أو الأمیلیز في الدم (وظیفة البنكریاس).<br />- ارتفاع نسبة البیلیروبین في الدم أو إنزیمات الكبد (وظائف الكبد).<br />- انخفاض أو ارتفاع مستوى الأنسولین في الدم (ھرمون ینظم مستوى السكر في الدم).<br />- انخفاض أو ارتفاع نسبة السكر أو ارتفاع نسبة الدھون (بما في ذلك الكولیسترول) في الدم<br />- ارتفاع مستوى ھرمون الغدة الدرقیة (ھرمون ینظم مستوى الكالسیوم والفوسفور) في الدم<br />- تغیر في بروتینات الدم (انخفاض مستوى الجلوبیولین أو وجود البروتین).<br />- إرتفاع نسبة البوتاسیوم ، الكالسیوم ، الفوسفور أو حمض البولیك في الدم.<br />نیلو كبسول ۱٥۰ ملجرام<br />- ارتفاع نسبة الفوسفاتیز القلویة في الدم</p><p>انخفاض نسبة البوتاسیوم أو الكالسیوم في الدم.<br />نیلو كبسول ۲۰۰ ملجرام<br />- ارتفاع نسبة الكریاتینین أو الیوریا في الدم (وظائف الكلى).<br />- ارتفاع مستویات الإنزیمات في الدم (الفوسفاتیز القلوي ، نازعة ھیدروجین اللاكتات أو فوسفوكیناز الكریاتین).<br />- انخفاض نسبة الماغنیسیوم أو البوتاسیوم أو الصودیوم أو الكالسیوم أو الفوسفور في الدم.<br />الإبلاغ عن الأعراض الجانبیة:<br />إذا ظھرت لدیك أي آثار جانبیة ، تحدث إلى طبیبك أو الصیدلي. یتضمن ذلك أي آثار جانبیة محتملة غیر مذكورة في ھذه النشرة. من<br />خلال الإبلاغ عن الأعراض الجانبیة ، یمكنك المساعدة في توفیر مزید من المعلومات حول سلامة ھذا الدواء.<br />الإبلاغ عن الأعراض الجانبیة المشتبھ بھ ا<br />من المھم الإبلاغ عن ردود الفعل السلبیة المشتبھ بھا بعد الحصول على ترخیص من المنتج الطبي. یسمح بالمراقبة المستمرة لتوازن<br />الفوائد / المخاطر للمنتج الطبي. یطُلب من المتخصصین في الرعایة الصحیة الإبلاغ عن أي ردود فعل سلبیة مشتبھ بھا (انظر التفاصیل<br />أدناه) .<br />الإبلاغ عن الأعراض الجانبیة المشتبھ بھ ا<br />المملكة العربیة السعودیة:<br />&bull; المركز الوطني للتیقظ الدوائي:<br />&bull; مركز الاتصال بالھیئة العامة للغذاء والدواء 19999:<br />npc.drug@sfda.gov.sa: &bull; البرید الإلكتروني<br />https://ade.sfda.gov.sa : &bull; الموقع الإلكتروني<br />دول الخلیج العربي الأخرى:<br />&bull; الرجاء الاتصال بالجھات الوطنیة في كل دولة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ في درجة حرارة أقل من ۳۰ درجة مئویة.<br />&bull; یجب التخزین في العلبة الأصلیة لحمایتھ من الرطوبة.<br />&bull; لا تستخدم نیلو إذا لاحظت أن العبوة تالفة أو تظھر علیھا علامات العبث.<br />&bull; احفظ ھذا الدواء بعیدًا عن رؤیة ومتناول أیدي الأطفال.<br />یشیر تاریخ انتھاء الصلاحیة إلى الیوم .EXP &bull; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العبوة بعد<br />الأخیر من الشھر.<br />&bull; لا تتخلص من الأدویة في میاه الصرف الصحي أو النفایات المنزلیة. اسأل&nbsp;الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد<br />بحاجة إلیھا. ستساعد ھذه الإجراءات في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ھي نیلوتینیب ھیدروكلورید ثنائي الھیدرات.<br />نیلو كبسول ۱٥۰ ملجرام:<br />تحتوي كل كبسولة جیلاتینیة صلبة على نیلوتینیب ھیدروكلورید ثنائي ھیدرات ما یعادل نیلوتینیب ۱٥۰ ملجرام.<br />الصواغات الأخرى ھي: ثاني أكسید السیلیكون الغرواني ، ثنائي فوسفات الكالسیوم ثنائي الھیدرات ، الجیلاتین ، أكسید الحدید الأصفر ،<br />ستیرات الماغنیسیوم ، البوفیدون ، كبریتات لوریل الصودیوم ، ثاني أكسید التیتانیوم وأكسید الحدید الأحمر.<br />یحتوي حبر الطباعة على الشیلاك والبروبیلین جلیكول ومحلول الأمونیا القوي وھیدروكسید البوتاسیوم وأكسید الحدید الأسود.<br />نیلو كبسول ۲۰۰ ملجرام:<br />تحتوي كل كبسولة جیلاتینیة صلبة على نیلوتینیب ھیدروكلورید ثنائي ھیدرات ما یعادل نیلوتینیب ۲۰۰ ملجرام.<br />الصواغات الأخرى ھي: ثاني أكسید السیلیكون الغرواني ، ثنائي فوسفات الكالسیوم ثنائي الھیدرات ، الجیلاتین ، أكسید الحدید الأصفر ،<br />ستیرات الماغنیسیوم ، البوفیدون ، كبریتات لوریل الصودیوم وثاني أكسید التیتانیوم.<br />یحتوي حبر الطباعة على الشیلاك والبروبیلین جلیكول ومحلول الأمونیا القوي وأكسید الحدید الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>نیلو كبسول ۱٥۰ ملجرام:<br />على الغطاء و &#39;H&#39; كبسولات جیلاتینیة صلبة مقاس &quot; ۱&rdquo;غطاء الكبسولات أحمر معتم وجسم الكبسولات أحمر غیر شفاف مطبوع علیھا<br />۲۳ &#39; على الجسم ، ملیئة بمسحوق حبیبي أصفر باھت إلى اللون الأصفر. &#39;<br />نیلو كبسول ۲۰۰ ملجرام:<br />على الغطاء &#39;H&#39; كبسولات جیلاتینیة صلبة مقاس &rdquo; 0&ldquo; غطاء الكبسولات أصفر غیر شفاف معتم وجسم الكبسولات أصفر مطبوع علیھا<br />و &#39; ۲٤ &#39; على الجسم ، ملیئة بمسحوق حبیبي أصفر باھت إلى اللون الأصفر.<br />كیفیة توفیر نیلو كبسول؟<br />یتم توفیر كبسول نیلو في عبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة اماروكس السعودیة الصناعیة<br />شارع الجامعة &ndash; الملز &ndash; الریاض ۱۱٤٤۱<br />المملكة العربیة السعودیة.<br />+ تلیفون: 966114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر/ ۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
1.	Name of The Medicinal Product
Nilo (Nilotinib Capsules 200 mg)


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.	Qualitative and Quantitative Composition Nilo (Nilotinib Capsules 200 mg):
Each Hard gelatin capsule contains Nilotinib Hydrochloride dihydrate equivalent to Nilotinib 200 mg.
r.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3.	Pharmaceutical Form
Capsule
Nilo (Nilotinib Capsules 200 mg)
Opaque Red cap & Opaque red body size '1' Hard gelatin capsules imprinted with 'H' on cap and '23' on body, filled with slightly yellow to yellowish granular powde
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp; </strong><strong>Therapeutic indications</strong></p><p>Nilo is indicated for the treatment of:</p><p>&nbsp;</p><p>-&nbsp;&nbsp; adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,</p><p>-&nbsp;&nbsp;&nbsp; adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,</p><p>-&nbsp;&nbsp; paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.</p><p>1.2&nbsp;&nbsp; Posology and method of administration</p><p>Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Treatment should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs.</p><p>If a dose is missed the patient should not take an additional dose, but take the usual prescribed next dose.</p><p><em><u>Posology for Philadelphia chromosome positive CML adult patients</u></em></p><p><em>&nbsp;</em></p><p>The recommended dose is:</p><p>&nbsp;</p><p>-&nbsp; 300 mg twice daily in newly diagnosed patients with CML in the chronic phase,</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; 400 mg twice daily in patients with chronic or accelerated phase CML with resistance or intolerance to prior therapy.</p><p>For a dose of 300 mg twice daily, 150 mg hard capsules are available.</p><p>&nbsp;</p><p><em><u>Posology for Philadelphia chromosome positive CML paediatric patients</u></em></p><p><em>&nbsp;</em></p><p>Dosing in paediatric patients is individualised and is based on body surface area (mg/m2). The recommended dose of nilotinib is 230 mg/m2 twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg) (see Table 1). Different strengths of Nilo hard capsules can be combined to attain the desired dose.</p><p>There is no experience with treatment of paediatric patients below 2 years of age. There are no data in newly diagnosed paediatric patients below 10 years of age and limited data in imatinib- resistant or intolerant paediatric patients below 6 years of age.</p><p>Table 1 Paediatric dosing scheme of nilotinib 230 mg/m2 twice daily</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body Surface Area (BSA)</strong></p></td><td style="vertical-align:top"><p><strong>Dose in mg (twice daily)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Up to 0.32 m2</p></td><td style="vertical-align:top"><p>50 mg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>0.33 &ndash; 0.54 m2</p></td><td style="vertical-align:top"><p>100 mg</p></td></tr><tr><td style="vertical-align:top"><p>0.55 &ndash; 0.76 m2</p></td><td style="vertical-align:top"><p>150 mg</p></td></tr><tr><td style="vertical-align:top"><p>0.77 &ndash; 0.97 m2</p></td><td style="vertical-align:top"><p>200 mg</p></td></tr><tr><td style="vertical-align:top"><p>0.98 &ndash; 1.19 m2</p></td><td style="vertical-align:top"><p>250 mg</p></td></tr><tr><td style="vertical-align:top"><p>1.20 &ndash; 1.41 m2</p></td><td style="vertical-align:top"><p>300 mg</p></td></tr><tr><td style="vertical-align:top"><p>1.42 &ndash; 1.63 m2</p></td><td style="vertical-align:top"><p>350 mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge;1.64 m2</p></td><td style="vertical-align:top"><p>400 mg</p></td></tr></tbody></table><p><em><u>Adult Philadelphia chromosome positive</u></em><em> <u>CML patients in chronic phase who have been treated</u> <u>with nilotinib as first</u></em><u>-<em>line therapy and who achieved a sustained deep molecular response</em></u><em> <u>(MR4.5)</u></em></p><p>Discontinuation of treatment may be considered in eligible adult Philadelphia chromosome positive (Ph+) CML patients in chronic phase who have been treated with nilotinib at 300 mg twice daily for a minimum of 3 years if a deep molecular response is sustained for a minimum of one year immediately prior to discontinuation of therapy. Discontinuation of nilotinib therapy should be initiated by a physician experienced in the treatment of patients with CML (see sections 4.4 and 5.1).</p><p>Eligible patients who discontinue nilotinib therapy must have their BCR-ABL transcript levels and complete blood count with differential monitored monthly for one year, then every 6 weeks for the second year, and every 12 weeks thereafter. Monitoring of BCR-ABL transcript levels must be performed with a quantitative diagnostic test validated to measure molecular response levels on the International Scale (IS) with a sensitivity of at least MR4.5 (BCR-ABL/ABL</p><p>&le;0.0032% IS).</p><p>&nbsp;</p><p>For patients who lose MR4 (MR4=BCR-ABL/ABL &le;0.01%IS) but not MMR (MMR=BCR- ABL/ABL &le;0.1%IS) during the treatment-free phase, BCR-ABL transcript levels should be monitored every 2 weeks until BCR-ABL levels return to a range between MR4 and MR4.5.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients who maintain BCR-ABL levels between MMR and MR4 for a minimum of 4 consecutive measurements can return to the original monitoring schedule.</p><p>Patients who lose MMR must re-initiate treatment within 4 weeks of when loss of remission is known to have occurred. Nilotinib therapy should be re-initiated at 300 mg twice daily or at a reduced dose level of 400 mg once daily if the patient had a dose reduction prior to discontinuation of therapy. Patients who re-initiate nilotinib therapy should have their BCR-ABL transcript levels monitored monthly until MMR is re-established and every 12 weeks thereafter (see section 4.4).</p><p><em><u>Adult Philadelphia chromosome positive CML patients in chronic phase who have achieved a</u></em><em> <u>sustained deep molecular response (MR 4.5) on nilotinib following prior imatinib therapy</u></em></p><p>Discontinuation of treatment may be considered in eligible adult Philadelphia chromosome positive (Ph+) CML patients in chronic phase who have been treated with nilotinib for a minimum of 3 years if a deep molecular response is sustained for a minimum of one year immediately prior to discontinuation of therapy. Discontinuation of nilotinib therapy should be initiated by a physician experienced in the treatment of patients with CML (see sections 4.4 and 5.1).</p><p>Eligible patients who discontinue nilotinib therapy must have their BCR-ABL transcript levels and complete blood count with differential monitored monthly for one year, then every 6 weeks for the second year, and every 12 weeks thereafter. Monitoring of BCR-ABL transcript levels must be performed with a quantitative diagnostic test validated to measure molecular response levels on the International Scale (IS) with a sensitivity of at least MR4.5 (BCR-ABL/ABL</p><p>&le;0.0032% IS).</p><p>&nbsp;</p><p>Patients with confirmed loss of MR4 (MR4= BCR-ABL/ABL &le;0.01%IS) during the treatment- free phase (two consecutive measures separated by at least 4 weeks showing loss of MR4) or loss of major molecular response (MMR=BCR-ABL/ABL &le;0.1%IS) must re-initiate treatment within 4 weeks of when loss of remission is known to have occurred. Nilotinib therapy should be re- initiated at either 300 mg or 400 mg twice daily. Patients who re-initiate nilotinib therapy should</p><p>&nbsp;</p><p>&nbsp;</p><p>have their BCR-ABL transcript levels monitored monthly until previous major molecular response or MR4 level is re-established and every 12 weeks thereafter (see section 4.4).</p><p><em><u>Dose adjustments or modifications</u></em></p><p><em>&nbsp;</em></p><p>Nilo may need to be temporarily withheld and/or dose reduced for haematological toxicities (neutropenia, thrombocytopenia) that are not related to the underlying leukaemia (see Table 2).</p><p>Table 2 Dose adjustments for neutropenia and thrombocytopenia</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Adult patients with newly diagnosed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phase CML at 300 mg twice daily and</p><p>imatinib-resistant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or intolerant CML in chronic phase at 400 mg twice daily</p></td><td style="vertical-align:top"><p>ANC* &lt;1.0 x 109/l and/or platelet counts &lt;50 x 109/l</p></td><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with nilotinib must be interrupted and blood count monitored.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment must be resumed within 2 weeks at prior dose if ANC &gt;1.0 x 109/l and/or platelets &gt;50 x 109/l.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If blood counts remain low, a dose reduction to 400 mg once daily may be required.</p></td></tr><tr><td style="vertical-align:top"><p>Adult patients with imatinib-resistant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or</p><p>intolerant CML in accelerated phase at 400 mg twice daily</p></td><td style="vertical-align:top"><p>ANC* &lt;0.5 x 109/l and/or platelet counts &lt;10 x 109/l</p></td><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with nilotinib must be interrupted and blood count monitored.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment must be resumed within 2 weeks at prior dose if ANC &gt;1.0 x 109/l and/or platelets &gt;20 x 109/l.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If blood counts remain low, a dose reduction to 400 mg once daily may be required.</p></td></tr><tr><td style="vertical-align:top"><p>Paediatric patients with newly diagnosed CML in chronic phase&nbsp; at&nbsp; 230 mg/m2 twice daily</p></td><td style="vertical-align:top"><p>ANC* &lt;1.0 x 109/l and/or platelet counts &lt;50 x 109/l</p></td><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nilotinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; must&nbsp;&nbsp; be interrupted and blood count monitored.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment must be resumed within 2 weeks at prior dose if ANC &gt;1.5 x 109/l</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>and</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>and/or platelets &gt;75 x 109/l.</p></td></tr><tr><td style="vertical-align:top"><p>imatinib-resistant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or</p></td><td style="vertical-align:top"><p>3. If blood counts remain low, a dose</p></td></tr><tr><td style="vertical-align:top"><p>intolerant CML in chronic</p></td><td style="vertical-align:top"><p>reduction to 230 mg/m2 once daily may be</p></td></tr><tr><td style="vertical-align:top"><p>phase at 230 mg/m2 twice</p></td><td style="vertical-align:top"><p>required.</p></td></tr><tr><td style="vertical-align:top"><p>daily</p></td><td style="vertical-align:top"><p>4. If event occurs after dose reduction,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>consider discontinuing treatment.</p></td></tr></tbody></table><p>*ANC = absolute neutrophil count</p><p>&nbsp;</p><p>If clinically significant moderate or severe non-haematological toxicity develops, dosing should be interrupted, and patients should be monitored and treated accordingly. If the prior dose was 300 mg twice daily in adult newly diagnosed patients with CML in the chronic phase, or 400 mg twice daily in adult patients with imatinib-resistant or intolerant CML in chronic or accelerated phase, or 230 mg/m2 twice daily in paediatric patients, dosing may be resumed at 400 mg once daily in adult patients and at 230 mg/m2 once daily in paediatric patients once the toxicity has resolved. If the prior dose was 400 mg once daily in adult patients or 230 mg/m2 once daily in paediatric patients, treatment should be discontinued. If clinically appropriate, re-escalation of the dose to the starting dose of 300 mg twice daily in adult newly diagnosed patients with CML in the chronic phase or to 400 mg twice daily in adult patients with imatinib-resistant or intolerant CML in chronic or accelerated phase or to 230 mg/m2 twice daily in paediatric patients should be considered.</p><p>Elevated serum lipase: For Grade 3-4 serum lipase elevations, doses in adult patients should be reduced to 400 mg once daily or interrupted. In paediatric patients, treatment must be interrupted until the event returns to Grade &le;1. Thereafter, if the prior dose was 230 mg/m2 twice daily, treatment can be resumed at 230 mg/m2 once daily. If the prior dose was 230 mg/m2 once daily, treatment should be discontinued. Serum lipase levels should be tested monthly or as clinically indicated (see section 4.4).</p><p>Elevated bilirubin and hepatic transaminases: For Grade 3-4 bilirubin and hepatic transaminase elevations in adult patients, doses should be reduced to 400 mg once daily or interrupted. For</p><p>&nbsp;</p><p>&nbsp;</p><p>Grade &ge;2 bilirubin elevations or Grade &ge;3 hepatic transaminase elevations in paediatric patients, treatment must be interrupted until the levels return to Grade &le;1. Thereafter, if the prior dose was 230 mg/m2 twice daily, treatment can be resumed at 230 mg/m2 once daily. If the prior dose was 230 mg/m2 once daily, and recovery to Grade &le;1 takes longer than 28 days, treatment should be discontinued. Bilirubin and hepatic transaminases levels should be tested monthly or as clinically indicated.</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p><em>&nbsp;</em></p><p>Approximately 12% of subjects in the Phase III study in patients with newly diagnosed CML in chronic phase and approximately 30% of subjects in the Phase II study in patients with imatinib- resistant or intolerant CML in chronic phase and accelerated phase were 65 years of age or over. No major differences were observed for safety and efficacy in patients &ge;65 years of age as compared to adults aged 18 to 65 years.</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>Clinical studies have not been performed in patients with impaired renal function.</p><p>&nbsp;</p><p>Since nilotinib and its metabolites are not renally excreted, a decrease in total body clearance is not anticipated in patients with renal impairment.</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Hepatic impairment has a modest effect on the pharmacokinetics of nilotinib. Dose adjustment is not considered necessary in patients with hepatic impairment. However, patients with hepatic impairment should be treated with caution (see section 4.4).</p><p><em>Cardiac disorders</em></p><p><em>&nbsp;</em></p><p>In clinical studies, patients with uncontrolled or significant cardiac disease (e.g., recent myocardial infarction, congestive heart failure, unstable angina or clinically significant</p><p>&nbsp;</p><p>&nbsp;</p><p>bradycardia) were excluded. Caution should be exercised in patients with relevant cardiac disorders (see section 4.4).</p><p>Increases in total serum cholesterol levels have been reported with nilotinib therapy (see section 4.4). Lipid profiles should be determined prior to initiating nilotinib therapy, assessed at month 3 and 6 after initiating therapy and at least yearly during chronic therapy.</p><p>Increases in blood glucose levels have been reported with nilotinib therapy (see section 4.4). Blood glucose levels should be assessed prior to initiating nilotinib therapy and monitored during treatment.</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of Nilo in paediatric patients with Philadelphia chromosome positive CML in chronic phase from 2 to less than 18 years of age have been established (see sections 4.8, 5.1 and 5.2). There is no experience in paediatric patients below 2 years of age or in paediatric patients with Philadelphia chromosome positive CML in accelerated phase or blast crisis. There are no data in newly diagnosed paediatric patients below 10 years of age and limited data in imatinib-resistant or intolerant paediatric patients below 6 years of age.</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Nilo should be taken twice daily approximately 12 hours apart and must not be taken with food. The hard capsules should be swallowed whole with water. No food should be consumed for 2 hours before the dose is taken and no food should be consumed for at least one hour after the dose is taken.</p><p>For patients who are unable to swallow hard capsules, the content of each hard capsule may be dispersed in one teaspoon of apple sauce (pur&eacute;ed apple) and should be taken immediately. Not more than one teaspoon of apple sauce and no food other than apple sauce must be used (see sections 4.4 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Myelosuppression</u></p><p>&nbsp;</p><p>Treatment with nilotinib is associated with (National Cancer Institute Common Toxicity Criteria grade 3-4) thrombocytopenia, neutropenia and anaemia. Occurrence is more frequent in patients with imatinib-resistant or intolerant CML, in particular in patients with accelerated-phase CML. Complete blood counts should be performed every two weeks for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Nilo temporarily or dose reduction (see section 4.2).</p><p><u>QT prolongation</u></p><p>&nbsp;</p><p>Nilotinib has been shown to prolong cardiac ventricular repolarisation as measured by the QT interval on the surface ECG in a concentration-dependent manner in adult and paediatric patients.</p><p>In the Phase III study in patients with newly diagnosed CML in chronic phase receiving 300 mg nilotinib twice daily, the change from baseline in mean time-averaged QTcF interval at steady state was 6 msec. No patient had a QTcF &gt;480 msec. No episodes of torsade de pointes were observed.</p><p>In the Phase II study in imatinib-resistant and intolerant CML patients in chronic and accelerated phase receiving 400 mg nilotinib twice daily, the change from baseline in mean time-averaged QTcF interval at steady state was 5 and 8 msec, respectively. QTcF of &gt;500 msec was observed in &lt;1% of these patients. No episodes of torsade de pointes were observed in clinical studies.</p><p>In a healthy volunteer study with exposures that were comparable to the exposures observed in patients, the time-averaged mean placebo-subtracted QTcF change from baseline was 7 msec (CI</p><p>&plusmn; 4 msec). No subject had a QTcF &gt;450 msec. Additionally, no clinically relevant arrhythmias were observed during the conduct of the trial. In particular, no episodes of torsade de pointes (transient or sustained) were observed.</p><p>&nbsp;</p><p>&nbsp;</p><p>Significant prolongation of the QT interval may occur when nilotinib is inappropriately taken with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong the QT interval, and/or food (see section 4.5). The presence of hypokalaemia and hypomagnesaemia may further enhance this effect. Prolongation of the QT interval may expose patients to the risk of fatal outcome.</p><p>Nilo should be used with caution in patients who have or who are at significant risk of developing prolongation of QTc, such as those:</p><p>-&nbsp; with congenital long QT prolongation</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; with uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia.</p><p>-&nbsp; taking anti-arrhythmic medicinal products or other substances that lead to QT prolongation.</p><p>&nbsp;</p><p>Close monitoring for an effect on the QTc interval is advisable and a baseline ECG is recommended prior to initiating nilotinib therapy and as clinically indicated. Hypokalaemia or hypomagnesaemia must be corrected prior to Nilo administration and should be monitored periodically during therapy.</p><p><u>Sudden death</u></p><p>&nbsp;</p><p>Uncommon cases (0.1 to 1%) of sudden deaths have been reported in patients with imatinib- resistant or intolerant CML in chronic phase or accelerated phase with a past medical history of cardiac disease or significant cardiac risk factors. Co-morbidities in addition to the underlying malignancy were also frequently present as were concomitant medicinal products. Ventricular repolarisation abnormalities may have been contributory factors. No cases of sudden death were reported in the Phase III study in newly diagnosed patients with CML in chronic phase.</p><p><u>Fluid retention and oedema</u></p><p>&nbsp;</p><p>Severe forms of drug-related fluid retention such as pleural effusion, pulmonary oedema, and pericardial effusion were uncommonly (0.1 to 1%) observed in a Phase III study of newly</p><p>&nbsp;</p><p>&nbsp;</p><p>diagnosed CML patients. Similar events were observed in post-marketing reports. Unexpected, rapid weight gain should be carefully investigated. If signs of severe fluid retention appear during treatment with nilotinib, the aetiology should be evaluated and patients treated accordingly (see section 4.2 for instructions on managing non-haematological toxicities).</p><p><u>Cardiovascular events</u></p><p>&nbsp;</p><p>Cardiovascular events were reported in a randomised Phase III study in newly diagnosed CML patients and observed in post-marketing reports. In this clinical study with a median on-therapy time of 60.5 months, Grade 3-4 cardiovascular events included peripheral arterial occlusive disease (1.4% and 1.1% at 300 mg and 400 mg nilotinib twice daily, respectively), ischaemic heart disease (2.2% and 6.1% at 300 mg and 400 mg nilotinib twice daily, respectively) and ischaemic cerebrovascular events (1.1% and 2.2% at 300 mg and 400 mg nilotinib twice daily, respectively). Patients should be advised to seek immediate medical attention if they experience acute signs or symptoms of cardiovascular events. The cardiovascular status of patients should be evaluated and cardiovascular risk factors monitored and actively managed during nilotinib therapy according to standard guidelines. Appropriate therapy should be prescribed to manage cardiovascular risk factors (see section 4.2 for instructions on managing non-haematological toxicities).</p><p><u>Hepatitis B reactivation</u></p><p>&nbsp;</p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.</p><p>Patients should be tested for HBV infection before initiating treatment with nilotinib. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with nilotinib should be closely monitored for signs and symptoms of active HBV</p><p>&nbsp;</p><p>&nbsp;</p><p>infection throughout therapy and for several months following termination of therapy (see section 4.8).</p><p><u>Special monitoring of adult Ph+ CML patients in chronic phase who have achieved a sustained</u> <u>deep molecular response</u></p><p><em><u>Eligibility for discontinuation of treatment</u></em></p><p><em>&nbsp;</em></p><p>Eligible patients who are confirmed to express the typical BCR-ABL transcripts, e13a2/b2a2 or e14a2/b3a2, can be considered for treatment discontinuation. Patients must have typical BCR- ABL transcripts to allow quantitation of BCR-ABL, evaluation of the depth of molecular response, and determination of a possible loss of molecular remission after discontinuation of treatment with nilotinib.</p><p><em><u>Monitoring of patients who have discontinued therapy</u></em></p><p><em>&nbsp;</em></p><p>Frequent monitoring of BCR-ABL transcript levels in patients eligible for treatment discontinuation must be performed with a quantitative diagnostic test validated to measure molecular response levels with a sensitivity of at least MR4.5 (BCR-ABL/ABL &le;0.0032% IS). BCR-ABL transcript levels must be assessed prior to and during treatment discontinuation (see sections 4.2 and 5.1).</p><p>Loss of major molecular response (MMR=BCR-ABL/ABL &le;0.1%IS) in CML patients who received nilotinib as first- or second-line therapy, or confirmed loss of MR4 (two consecutive measures separated by at least 4 weeks showing loss of MR4 (MR4=BCR-ABL/ABL</p><p>&le;0.01%IS)) in CML patients who received nilotinib as second-line therapy will trigger treatment re-initiation within 4 weeks of when loss of remission is known to have occurred. Molecular relapse can occur during the treatment-free phase, and long-term outcome data are not yet available. It is therefore crucial to perform frequent monitoring of BCR-ABL transcript levels and complete blood count with differential in order to detect possible loss of remission (see section 4.2). For patients who fail to achieve MMR after three months of treatment re-initiation, BCR-ABL kinase domain mutation testing should be performed.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Laboratory tests and monitoring</u></p><p>&nbsp;</p><p><em><u>Blood lipids</u></em></p><p><em>&nbsp;</em></p><p>In a Phase III study in newly diagnosed CML patients, 1.1% of the patients treated with 400 mg nilotinib twice daily showed a Grade 3-4 elevation in total cholesterol; no Grade 3-4 elevations were however observed in the 300 mg twice daily dose group (see section 4.8). It is recommended that the lipid profiles be determined before initiating treatment with nilotinib, assessed at month 3 and 6 after initiating therapy and at least yearly during chronic therapy (see section 4.2). If a HMG-CoA reductase inhibitor (a lipid-lowering agent) is required, please refer to section 4.5 before initiating treatment since certain HMG-CoA reductase inhibitors are also metabolised by the CYP3A4 pathway.</p><p><em><u>Blood glucose</u></em></p><p><em>&nbsp;</em></p><p>In a Phase III study in newly diagnosed CML patients, 6.9% and 7.2% of the patients treated with 400 mg nilotinib and 300 mg nilotinib twice daily, respectively, showed a Grade 3-4 elevation in blood glucose. It is recommended that the glucose levels be assessed before initiating treatment with Nilo and monitored during treatment, as clinically indicated (see section 4.2). If test results warrant therapy, physicians should follow their local standards of practice and treatment guidelines.</p><p><u>Interactions with other medicinal products</u></p><p>&nbsp;</p><p>The administration of Nilo with agents that are strong CYP3A4 inhibitors (including, but not limited to, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir) should be avoided. Should treatment with any of these agents be required, it is recommended that nilotinib therapy be interrupted if possible (see section 4.5). If transient interruption of treatment is not possible, close monitoring of the individual for prolongation of the QT interval is indicated (see sections 4.2, 4.5 and 5.2).</p><p>Concomitant use of nilotinib with medicinal products that are potent inducers of CYP3A4 (e.g., phenytoin, rifampicin, carbamazepine, phenobarbital and St. John&#39;s Wort) is likely to reduce</p><p>&nbsp;</p><p>&nbsp;</p><p>exposure to nilotinib to a clinically relevant extent. Therefore, in patients receiving nilotinib, co- administration of alternative therapeutic agents with less potential for CYP3A4 induction should be selected (see section 4.5).</p><p><u>Food effect</u></p><p>&nbsp;</p><p>The bioavailability of Nilo is increased by food. Nilotinib must not be taken in conjunction with food (see sections 4.2 and 4.5) and should be taken 2 hours after a meal. No food should be consumed for at least one hour after the dose is taken. Grapefruit juice and other foods that are known to inhibit CYP3A4 should be avoided. For patients who are unable to swallow hard capsules, the content of each hard capsule may be dispersed in one teaspoon of apple sauce and should be taken immediately. Not more than one teaspoon of apple sauce and no food other than apple sauce must be used (see section 5.2).</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Hepatic impairment has a modest effect on the pharmacokinetics of nilotinib. Single dose administration of 200 mg of nilotinib resulted in increases in AUC of 35%, 35% and 19% in subjects with mild, moderate and severe hepatic impairment, respectively, compared to a control group of subjects with normal hepatic function. The predicted steady-state Cmax of nilotinib showed an increase of 29%, 18% and 22%, respectively. Clinical studies have excluded patients with alanine transaminase (ALT) and/or aspartate transaminase (AST) &gt;2.5 (or &gt;5, if related to disease) times the upper limit of the normal range and/or total bilirubin &gt;1.5 times the upper limit of the normal range. Metabolism of nilotinib is mainly hepatic. Patients with hepatic impairment might therefore have increased exposure to nilotinib and should be treated with caution (see section 4.2).</p><p><u>Serum lipase</u></p><p>&nbsp;</p><p>Elevation in serum lipase has been observed. Caution is recommended in patients with previous history of pancreatitis. In case lipase elevations are accompanied by abdominal symptoms,</p><p>&nbsp;</p><p>&nbsp;</p><p>nilotinib therapy should be interrupted and appropriate diagnostic measures considered to exclude pancreatitis.</p><p><u>Total gastrectomy</u></p><p>&nbsp;</p><p>The bioavailability of nilotinib might be reduced in patients with total gastrectomy (see section 5.2). More frequent follow-up of these patients should be considered.</p><p><u>Tumour lysis syndrome</u></p><p>&nbsp;</p><p>Due to possible occurrence of tumour lysis syndrome (TLS) correction of clinically significant dehydration and treatment of high uric acid levels are recommended prior to initiating nilotinib therapy (see section 4.8).</p><p><u>Lactose</u></p><p>&nbsp;</p><p>Nilotinib hard capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Laboratory abnormalities of mild to moderate transient elevations of aminotransferases and total bilirubin have been observed in children at a higher frequency than in adults, indicating a higher risk of hepatotoxicity in the paediatric population (see section 4.8). Liver function (bilirubin and hepatic transaminases levels) should be monitored monthly or as clinically indicated. Elevations of bilirubin and hepatic transaminases should be managed by withholding nilotinib temporarily, dose reduction and/or discontinuation of nilotinib (see section 4.2). The long-term effects of prolonged treatment with nilotinib in paediatric patients are unknown. In a study in the CML paediatric population, growth retardation has been documented in patients treated with nilotinib (see section 4.8). Close monitoring of growth in paediatric patients under nilotinib treatment is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nilo may be given in combination with haematopoietic growth factors such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) if clinically indicated. It may be given with hydroxyurea or anagrelide if clinically indicated.</p><p>Nilotinib is mainly metabolised in the liver with CYP3A4 expected to be the main contributor to the oxidative metabolism. Nilotinib is also a substrate for the multi-drug efflux pump, P- glycoprotein (P-gp). Therefore, absorption and subsequent elimination of systemically absorbed nilotinib may be influenced by substances that affect CYP3A4 and/or P-gp.</p><p><u>Substances that may increase nilotinib serum concentrations</u></p><p>&nbsp;</p><p>Concomitant administration of nilotinib with imatinib (a substrate and moderator of P-gp and CYP3A4), had a slight inhibitory effect on CYP3A4 and/or P-gp. The AUC of imatinib was increased by 18% to 39%, and the AUC of nilotinib was increased by 18% to 40%. These changes are unlikely to be clinically important.</p><p>The exposure to nilotinib in healthy subjects was increased 3-fold when co-administered with the strong CYP3A4 inhibitor ketoconazole. Concomitant treatment with strong CYP3A4 inhibitors, including ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, and telithromycin, should therefore be avoided (see section 4.4). Increased exposure to nilotinib might also be expected with moderate CYP3A4 inhibitors. Alternative concomitant medicinal products with no or minimal CYP3A4 inhibition should be considered.</p><p><u>Substances that may decrease nilotinib serum concentrations</u></p><p>&nbsp;</p><p>Rifampicin, a potent CYP3A4 inducer, decreases nilotinib Cmax by 64% and reduces nilotinib AUC by 80%. Rifampicin and nilotinib should not be used concomitantly.</p><p>The concomitant administration of other medicinal products that induce CYP3A4 (e.g. phenytoin, carbamazepine, phenobarbital and St. John&#39;s Wort) is likewise likely to reduce exposure to nilotinib to a clinically relevant extent. In patients for whom CYP3A4 inducers are indicated, alternative agents with less enzyme induction potential should be selected.</p><p>&nbsp;</p><p>&nbsp;</p><p>Nilotinib has pH dependent solubility, with lower solubility at higher pH. In healthy subjects receiving esomeprazole at 40 mg once daily for 5 days, gastric pH was markedly increased, but nilotinib absorption was only decreased modestly (27% decrease in Cmax and 34% decrease in AUC0-&infin;). Nilotinib may be used concurrently with esomeprazole or other proton pump inhibitors as needed.</p><p>In a healthy subjects study, no significant change in nilotinib pharmacokinetics was observed when a single 400 mg dose of nilotinib was administered 10 hours after and 2 hours before famotidine. Therefore, when the concurrent use of a H2 blocker is necessary, it may be administered approximately 10 hours before and approximately 2 hours after the dose of Nilotinib.</p><p>In the same study as above, administration of an antacid (aluminium hydroxide/magnesium hydroxide/simethicone) 2 hours before or after a single 400 mg dose of nilotinib also did not alter nilotinib pharmacokinetics. Therefore, if necessary, an antacid may be administered approximately 2 hours before or approximately 2 hours after the dose of Nilotinib.</p><p><u>Substances that may have their systemic concentration altered by nilotinib</u></p><p>&nbsp;</p><p><em>In vitro</em>, nilotinib is a relatively strong inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6 and UGT1A1, with Ki value being lowest for CYP2C9 (Ki=0.13 microM).</p><p>A single-dose drug-drug interaction study in healthy volunteers with 25 mg warfarin, a sensitive CYP2C9 substrate, and 800 mg nilotinib did not result in any changes in warfarin pharmacokinetic parameters or warfarin pharmacodynamics measured as prothrombin time (PT) and international normalised ratio (INR). There are no steady-state data. This study suggests that a clinically meaningful drug-drug interaction between nilotinib and warfarin is less likely up to a dose of 25 mg of warfarin. Due to lack of steady-state data, control of warfarin pharmacodynamic markers (INR or PT) following initiation of nilotinib therapy (at least during the first 2 weeks) is recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>In CML patients, nilotinib administered at 400 mg twice daily for 12 days increased the systemic exposure (AUC and Cmax) of oral midazolam (a substrate of CYP3A4) 2.6-fold and 2.0-fold, respectively. Nilotinib is a moderate CYP3A4 inhibitor. As a result, the systemic exposure of other medicinal products primarily metabolised by CYP3A4 (e.g. certain HMG-CoA reductase inhibitors) may be increased when co-administered with nilotinib. Appropriate monitoring and dose adjustment may be necessary for medicinal products that are CYP3A4 substrates and have a narrow therapeutic index (including but not limited to alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, sirolimus and tacrolimus) when co-administered with nilotinib.</p><p>The combination of nilotinib with those statins that are mainly eliminated by CYP3A4, may increase the potential for statin-induced myopathy, including rhabdomyolysis.</p><p><u>Anti-arrhythmic medicinal products and other substances that may prolong the QT interval</u></p><p>&nbsp;</p><p>Nilotinib should be used with caution in patients who have or may develop prolongation of the QT interval, including those patients taking anti-arrhythmic medicinal products such as amiodarone, disopyramide, procainamide, quinidine and sotalol or other medicinal products that may lead to QT prolongation such as chloroquine, halofantrine, clarithromycin, haloperidol, methadone and moxifloxacin (see section 4.4).</p><p><u>Food interactions</u></p><p>&nbsp;</p><p>The absorption and bioavailability of nilotinib are increased if it is taken with food, resulting in a higher serum concentration (see sections 4.2, 4.4 and 5.2). Grapefruit juice and other foods that are known to inhibit CYP3A4 should be avoided.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Women of childbearing potential have to use highly effective contraception during treatment with nilotinib and for up to two weeks after ending treatment.</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of nilotinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Nilo should not be used during pregnancy unless the clinical condition of the woman requires treatment with nilotinib. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.</p><p>If a woman who is being treated with nilotinib is considering pregnancy, treatment discontinuation may be considered based on the eligibility criteria for discontinuing treatment as described in sections 4.2 and 4.4. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate nilotinib treatment during pregnancy (see sections 4.2 and 4.4).</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether nilotinib is excreted in human milk. Available toxicological data in animals have shown excretion of nilotinib in milk (see section 5.3). Since a risk to the newborns/infants cannot be excluded, women should not breast<strong>-</strong>feed during Nilo treatment and for 2 weeks after the last dose.</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Animal studies did not show an effect on fertility in male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nilo has no or negligible influence on the ability to drive and use machines. However, it is recommended that patients experiencing dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The data described below reflect exposure to nilotinib in a total of 737 adult patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated at the recommended dose of 300 mg twice daily (n=279) and from an open-label multicentre Phase II study in adult patients with imatinib-resistant or intolerant CML in chronic phase (n=321) and accelerated phase (n=137) treated at the recommended dose of 400 mg twice daily. Safety information from two Nilo treatment discontinuation studies, and from a prospective non- interventional study in adult patients with imatinib-resistant or intolerant CML in chronic phase with a two-year observation period (n=507) is also provided.</p><p><em><u>In adult patients with newly diagnosed CML in chronic phase</u></em></p><p><em>&nbsp;</em></p><p>The median duration of exposure was 60.5 months (range 0.1-70.8 months).</p><p>&nbsp;</p><p>The most frequent (&ge;10%) non-haematological adverse reactions were rash, pruritus, headache, nausea, fatigue, alopecia, myalgia and upper abdominal pain. Most of these adverse reactions were mild to moderate in severity. Constipation, dry skin, asthenia, muscle spasms, diarrhoea, arthralgia, abdominal pain, vomiting and peripheral oedema were observed less commonly (&lt;10% and &ge;5%) were of mild to moderate severity, manageable and generally did not require dose reduction.</p><p>Treatment-emergent haematological toxicities include myelosuppression: thrombocytopenia (18%), neutropenia (15%) and anaemia (8%). Biochemical adverse drug reactions include alanine aminotransferase increased (24%), hyperbilirubinaemia (16%), aspartate aminotransferase increased (12%), lipase increased (11%), blood bilirubin increased (10%), hyperglycaemia (4%), hypercholesterolaemia (3%) and hypertriglyceridaemia (&lt;1%). Pleural and pericardial effusions, regardless of causality, occurred in 2% and &lt;1% of patients, respectively, receiving nilotinib 300 mg twice daily. Gastrointestinal haemorrhage, regardless of causality, was reported in 3% of these patients.</p><p>&nbsp;</p><p>&nbsp;</p><p>The change from baseline in mean time-averaged QTcF interval at steady state was 6 msec. No patient had an absolute QTcF &gt;500 msec while on the study medicinal product. QTcF increase from baseline exceeding 60 msec was observed in &lt;1% of patients while on the study medicinal product. No sudden deaths or episodes of torsade de pointes (transient or sustained) were observed. No decrease from baseline in mean left ventricular ejection fraction (LVEF) was observed at any time during treatment. No patient had a LVEF of &lt;45% during treatment nor an absolute reduction in LVEF of more than 15%.</p><p>Discontinuation due to adverse drug reactions was observed in 10% of patients.</p><p>&nbsp;</p><p><em><u>In adult patients with imatinib-resistant or intolerant CML in chronic phase and accelerated</u></em><em> <u>phase</u></em></p><p>The data described below reflect exposure to nilotinib in 458 adult patients in an open-label multicentre Phase II study in patients with imatinib-resistant or intolerant CML in chronic phase (n=321) and accelerated phase (n=137) treated at the recommended dose of 400 mg twice daily.</p><p>The most frequent (&ge;10%) non-haematological drug-related adverse events were rash, pruritus, nausea, fatigue, headache, vomiting, myalgia, constipation and diarrhoea. Most of these adverse events were mild to moderate in severity. Alopecia, muscle spasms, decreased appetite, arthralgia, abdominal pain, bone pain, peripheral oedema, asthenia, upper abdominal pain, dry skin, erythema and pain in extremity were observed less commonly (&lt;10% and &ge;5%) and have been of mild to moderate severity (Grade 1 or 2). Discontinuation due to adverse drug reactions was observed in 16% of chronic phase and 10% of accelerated phase patients.</p><p>Treatment-emergent haematological toxicities include myelosuppression: thrombocytopenia (31%), neutropenia (17%) and anaemia (14%). Pleural and pericardial effusions as well as complications of fluid retention occurred in &lt;1% of patients receiving Nilotinib. Cardiac failure was observed in &lt;1% of patients. Gastrointestinal and CNS haemorrhage were reported in 1% and &lt;1% of patients, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>QTcF exceeding 500 msec was observed in &lt;1% of patients. No episodes of torsade de pointes (transient or sustained) were observed.</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The adverse reactions are ranked under heading of frequency using the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><em><u>Most frequently reported adverse reactions in Nilo clinical studies</u></em></p><p><em>&nbsp;</em></p><p>Non-haematological adverse reactions (excluding laboratory abnormalities) that are reported in at least 5% of the adult patients in Nilotinib clinical studies that serve as the basis for the approved indications are shown in Table 3.</p><p>Table 3 Non-haematological adverse reactions (&ge;5% of all patients)*</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Newly diagnosed CML-CP 300 mg twice daily</strong></p><p><strong>n=279</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Imatinib-resistant or intolerant CML-CP and CML-AP</strong></p><p><strong>400 mg twice daily n=458</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>60-month analysis</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>24-month analysis</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; organ class/</strong>Adverse reaction</p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4</strong></p></td><td style="vertical-align:top"><p><strong>CML-CP n=321</strong></p><p><strong>Grade 3-</strong></p><p><strong>4</strong></p></td><td style="vertical-align:top"><p><strong>CML- AP n=137</strong></p><p><strong>Grade 3-4</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Decreased appetite **</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Upper abdominal pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>* Percentages are rounded to integer for presentation in this table. However, percentages with one decimal precision are used to identify terms with a frequency of at least 5% and to classify terms according to frequency categories.</p><p>**Also includes preferred term anorexia</p><p>&nbsp;</p><p>Adverse reactions that were reported in adult patients in the Nilo clinical studies which serve as a basis for the approved indications at a frequency of less than 5% are shown in Table 4. For laboratory abnormalities, very common adverse reactions not included in Table 3 are also reported. These adverse reactions are included based on clinical relevance.</p><p>Table 4 Adverse reactions in adult patients in Nilo clinical studies (&lt;5% of all patients)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Folliculitis,&nbsp;&nbsp; upper&nbsp;&nbsp;&nbsp; respiratory&nbsp;&nbsp;&nbsp; tract&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pharyngitis, nasopharyngitis, rhinitis), pneumonia*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Urinary tract infection, gastroenteritis, bronchitis, herpes virus infection, candidiasis (including oral candidiasis)</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Sepsis, subcutaneous abscess, anal abscess, furuncle, tinea pedis, hepatitis B reactivation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Skin papilloma</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Oral papilloma, paraproteinaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Leukopenia, eosinophilia, febrile neutropenia, pancytopenia, lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombocythaemia, leukocytosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hyperthyroidism, hypothyroidism</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hyperparathyroidism secondary, thyroiditis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypophosphataemia (including blood phosphorus decreased)</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Electrolyte imbalance (including hypomagnesaemia, hyperkalaemia, hypokalaemia, hyponatraemia, hypocalcaemia, hypercalcaemia, hyperphosphataemia),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mellitus,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperglycaemia, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dehydration, increased appetite, gout, dyslipidaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hyperuricaemia, hypoglycaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Depression, insomnia, anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Disorientation, confusional state, amnesia, dysphoria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness, peripheral neuropathy, hypoaesthesia, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Intracranial haemorrhage, ischaemic stroke, transient ischaemic attack, cerebral infarction, migraine, loss of consciousness (including syncope),</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tremor, disturbance in attention, hyperaesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Cerebrovascular&nbsp;&nbsp;&nbsp; accident,&nbsp;&nbsp;&nbsp; brain&nbsp;&nbsp;&nbsp; oedema,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; optic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neuritis,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lethargy, dysaesthesia, restless legs syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Eye haemorrhage, periorbital oedema, eye pruritus, conjunctivitis, dry eye (including xerophthalmia)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Visual impairment, vision blurred, conjunctival haemorrhage, visual acuity reduced, eyelid oedema, photopsia, hyperaemia (scleral, conjunctival, ocular), eye irritation</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Papilloedema, chorioretinopathy, diplopia, photophobia, eye swelling, blepharitis, eye pain, conjunctivitis allergic, ocular surface disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hearing impaired, ear pain, tinnitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Angina pectoris, arrhythmia (including atroventricular block, cardiac flutter, extrasystoles, tachycardia, atrial fibrillation, bradycardia), palpitations, electrocardiogram QT prolonged, cardiac failure*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Myocardial infarction, coronary artery disease, cardiac murmur, pericardial effusion, cyanosis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Ventricular dysfunction, pericarditis, ejection fraction decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypertension, flushing, peripheral artery stenosis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypertensive crisis, peripheral arterial occlusive disease, intermittent claudication, arterial stenosis limb, haematoma, arteriosclerosis</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Shock haemorrhagic, hypotension, thrombosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnoea, dyspnoea exertional, epistaxis, cough, dysphonia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pulmonary oedema, pleural effusion, interstitial lung disease, pleuritic pain, pleurisy, pharyngolaryngeal pain, throat irritation</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Pulmonary hypertension, wheezing, oropharyngeal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pancreatitis,&nbsp;&nbsp; abdominal&nbsp;&nbsp; discomfort,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal&nbsp;&nbsp; distension,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dysgeusia, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage, melaena, mouth ulceration, gastroesophageal reflux, stomatitis, oesophageal pain, dry mouth, gastritis, sensitivity of teeth</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Gastrointestinal ulcer perforation, retroperitoneal haemorrhage, haematemesis, gastric ulcer, oesophagitis ulcerative, subileus, enterocolitis, haemorrhoids, hiatus hernia, rectal haemorrhage, gingivitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia (including blood bilirubin increased)</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hepatotoxicity, toxic hepatitis, jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Cholestasis, hepatomegaly</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Night sweats, eczema, urticaria, hyperhidrosis, contusion, acne, dermatitis (including allergic, exfoliative and acneiform)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Exfoliative rash, drug eruption, skin pain, ecchymosis, swelling face</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Erythema multiforme, erythema nodosum, skin ulcer, palmar-plantar erythrodysaesthesia syndrome, petechiae, photosensitivity, blister, dermal</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cysts, sebaceous hyperplasia, skin atrophy, skin discolouration, skin exfoliation, skin hyperpigmentation, skin hypertrophy, hyperkeratosis, psoriasis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Musculoskeletal chest pain, musculoskeletal pain, back pain, flank pain, neck pain, muscular weakness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Musculoskeletal stiffness, joint swelling</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Arthritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pollakiuria, renal failure*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dysuria, micturition urgency, nocturia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Haematuria, urinary incontinence, chromaturia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Breast pain, gynaecomastia, erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Breast induration, menorrhagia, nipple swelling</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Chest pain (including non-cardiac chest pain), pain, pyrexia, chest discomfort, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Face oedema, gravitational oedema, influenza-like illness, chills, feeling body temperature change (including feeling hot, feeling cold)</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Localised oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased, aspartate aminotransferase increased, lipase increased, lipoprotein cholesterol (including low density and high density) increased, total cholesterol increased, blood triglycerides increased</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Haemoglobin decreased, blood amylase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, blood creatinine phosphokinase increased, weight decreased, weight increased, blood insulin increased, globulins decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blood lactate dehydrogenase increased, blood glucose decreased, blood urea increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Troponin increased, blood bilirubin unconjugated increased, blood insulin decreased, insulin C-peptide decreased, blood parathyroid hormone increased</p></td></tr></tbody></table><p>* Frequency estimates based on data from a prospective non-interventional study in adult patients with imatinib-resistant or intolerant CML in chronic phase with a two-year observation period (n=507)</p><p>Clinically relevant or severe abnormalities of routine haematological or biochemistry laboratory values in adult patients are presented in Table 5.</p><p>Table 5 Grade 3-4 laboratory abnormalities*</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Newly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diagnosed CML-CP</strong></p><p><strong>300 mg twice daily</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Imatinib-resistant or intolerant CML-CP and CML-AP</strong></p><p><strong>400 mg twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>n=279 (%)</strong></p></td><td style="vertical-align:top"><p><strong>CML-CP n=321 (%)</strong></p></td><td style="vertical-align:top"><p><strong>CML-AP n=137 (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Haematological parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Myelosuppression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- Neutropenia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>42</p></td></tr><tr><td style="vertical-align:top"><p>- Thrombocytopenia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>42</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- Anaemia</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p><strong>Biochemistry parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated creatinine</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated lipase</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated SGOT (AST)</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated SGPT (ALT)</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>- Hypophosphataemia</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated bilirubin (total)</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated glucose</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated cholesterol (total)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>**</p></td><td style="vertical-align:top"><p>**</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated triglycerides</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>**</p></td><td style="vertical-align:top"><p>**</p></td></tr></tbody></table><p>*Percentages with one decimal precision are used and rounded to integer for presentation in this table</p><p>**Parameters not collected</p><p>&nbsp;</p><p><u>Treatment discontinuation in adult Ph+ CML patients in chronic phase who have achieved a</u> <u>sustained deep molecular response</u></p><p>After discontinuation of nilotinib therapy within the framework of attempting TFR, patients may experience musculoskeletal symptoms more frequently than before treatment discontinuation, e.g., myalgia, pain in extremity, arthralgia, bone pain, spinal pain or musculoskeletal pain.</p><p>In a Phase II clinical study with newly diagnosed adult patients with Ph+ CML in chronic phase (N=190), musculoskeletal symptoms were reported within a year of Nilo discontinuation in 24.7% versus 16.3% within the previous year on nilotinib treatment.</p><p>In a Phase II clinical study with adult patients with Ph+ CML in chronic phase on nilotinib treatment and previously treated with imatinib (N=126), musculoskeletal symptoms were</p><p>&nbsp;</p><p>&nbsp;</p><p>reported within a year of discontinuation in 42.1% versus 14.3% within the previous year on nilotinib treatment.</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Sudden death</u></em></p><p><em>&nbsp;</em></p><p>Uncommon cases (0.1 to 1%) of sudden deaths have been reported in Nilotinib clinical trials and/or compassionate use programs in patients with imatinib-resistant or intolerant CML in chronic phase or accelerated phase with a past medical history of cardiac disease or significant cardiac risk factors (see section 4.4).</p><p><em><u>Hepatitis B reactivation</u></em></p><p><em>&nbsp;</em></p><p>Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome (see section 4.4).</p><p><u>Post-marketing experience</u></p><p>&nbsp;</p><p>The following adverse reactions have been derived from post-marketing experience with Nilotinib via spontaneous case reports, literature cases, expanded access programmes, and clinical studies other than the global registration trials. Since these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to nilotinib exposure.</p><p>Frequency very common: Growth retardation has been documented in paediatric patients treated with nilotinib.</p><p>Frequency rare: Cases of tumour lysis syndrome have been reported in patients treated with nilotinib.</p><p>Frequency unknown: Cases of facial paralysis have been reported in patients treated with nilotinib.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>&nbsp;</p><p>The safety of nilotinib in paediatric patients (from 2 to &lt;18 years of age) with Philadelphia chromosome positive CML in chronic phase (n=69) has been investigated in two studies (see section 5.1). In paediatric patients, the frequency, type and severity of adverse reactions observed have been generally consistent with those observed in adults, with the exception of the laboratory abnormalities hyperbilirubinaemia (Grade 3/4: 13.0%) and transaminase elevation (AST Grade 3/4: 1.4%, ALT Grade 3/4: 8.7%) which were reported at a higher frequency than in adult patients. Bilirubin and hepatic transaminase levels should be monitored during treatment (see sections 4.2 and 4.4).</p><p><em><u>Growth retardation in paediatric population</u></em></p><p><em>&nbsp;</em></p><p>In an interim analysis in a study in the CML paediatric population, with a median exposure of 33 months in each cohort (newly diagnosed and resistant or intolerant Ph+ CML-CP), growth retardation (crossing two main percentile lines from baseline) has been documented in 12.1%. Close monitoring of growth in paediatric patients under nilotinib treatment is recommended (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:66.6pt;margin-top:9.6pt;width:402.4pt;height:129.05pt;z-index:-251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:81.7pt;margin-bottom:
     0in;margin-left:13.3pt;margin-bottom:.0001pt;text-indent:-3.0pt;
     line-height:230%'>The National Pharmacovigilance and Drug Safety Centre
     (NPC) o SFDA Call Center: 19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:19.3pt;text-indent:-9.2pt;
     mso-list:l1 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:0in'><span style='font-size:13.0pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-top:8.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.2pt;
     mso-list:l1 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="541" height="176" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999
o	E-mail:npc.drug@sfda.gov.sa

o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated reports of intentional overdose with nilotinib were reported, where an unspecified number of Nilo hard capsules were ingested in combination with alcohol and other medicinal products. Events included neutropenia, vomiting and drowsiness. No ECG changes or hepatotoxicity were reported. Outcomes were reported as recovered.</p><p>In the event of overdose, the patient should be observed and appropriate supportive treatment given.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE08</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Nilotinib is a potent inhibitor of the ABL tyrosine kinase activity of the BCR-ABL oncoprotein both in cell lines and in primary Philadelphia-chromosome positive leukaemia cells. The substance binds with high affinity to the ATP-binding site in such a manner that it is a potent inhibitor of wild-type BCR-ABL and maintains activity against 32/33 imatinib-resistant mutant forms of BCR-ABL. As a consequence of this biochemical activity, nilotinib selectively inhibits the proliferation and induces apoptosis in cell lines and in primary Philadelphia-chromosome positive leukaemia cells from CML patients. In murine models of CML, as a single agent nilotinib reduces tumour burden and prolongs survival following oral administration.</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Nilotinib has little or no effect against the majority of other protein kinases examined, including Src, except for the PDGF, KIT and Ephrin receptor kinases, which it inhibits at concentrations within the range achieved following oral administration at therapeutic doses recommended for the treatment of CML (see Table 6).</p><p>Table 6 Kinase profile of nilotinib (phosphorylation IC50 nM)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>BCR-ABL</p></td><td style="vertical-align:top"><p>PDGFR</p></td><td style="vertical-align:top"><p>KIT</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>210</p></td></tr></tbody></table><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p><em><u>Clinical studies in newly diagnosed CML in chronic phase</u></em></p><p><em>&nbsp;</em></p><p>An open-label, multicentre, randomised Phase III study was conducted to determine the efficacy of nilotinib versus imatinib in 846 adult patients with cytogenetically confirmed newly diagnosed Philadelphia chromosome positive CML in the chronic phase. Patients were within six months of diagnosis and were previously untreated, with the exception of hydroxyurea and/or anagrelide. Patients were randomised 1:1:1 to receive either nilotinib 300 mg twice daily (n=282), nilotinib</p><p>400 mg twice daily (n=281) or imatinib 400 mg once daily (n=283). Randomisation was stratified by Sokal risk score at the time of diagnosis.</p><p>Baseline characteristics were well balanced between the three treatment arms. Median age was 47 years in both nilotinib arms and 46 years in the imatinib arm, with 12.8%, 10.0% and 12.4% of patients were &ge;65 years of age in the nilotinib 300 mg twice daily, nilotinib 400 mg twice daily and imatinib 400 mg once daily treatment arms, respectively. There were slightly more male than female patients (56.0%, 62.3% and 55.8%, in the nilotinib 300 mg twice daily, 400 mg twice daily and imatinib 400 mg once daily arm, respectively). More than 60% of all patients were Caucasian and 25% of all patients were Asian.</p><p>The primary data analysis time point was when all 846 patients completed 12 months of treatment (or discontinued earlier). Subsequent analyses reflect when patients completed 24, 36, 48, 60 and 72 months of treatment (or discontinued earlier). The median time on treatment was</p><p>&nbsp;</p><p>&nbsp;</p><p>approximately 70 months in the nilotinib treatment groups and 64 months in the imatinib group. The median actual dose intensity was 593 mg/day for nilotinib 300 mg twice daily, 772 mg/day for nilotinib 400 mg twice daily and 400 mg/day for imatinib 400 mg once daily. This study is ongoing.</p><p>The primary efficacy endpoint was major molecular response (MMR) at 12 months. MMR was defined as &le;0.1% BCR-ABL/ABL% by international scale (IS) measured by RQ-PCR, which corresponds to a &ge;3 log reduction of BCR-ABL transcript from standardised baseline. The MMR rate at 12 months was statistically significantly higher for nilotinib 300 mg twice daily compared to imatinib 400 mg once daily (44.3% versus 22.3%, p&lt;0.0001). The rate of MMR at 12 months, was also statistically significantly higher for nilotinib 400 mg twice daily compared to imatinib 400 mg once daily (42.7% versus 22.3%, p&lt;0.0001).</p><p>The rates of MMR at 3, 6, 9 and 12 months were 8.9%, 33.0%, 43.3% and 44.3% for nilotinib</p><p>300 mg twice daily, 5.0%, 29.5%, 38.1% and 42.7% for nilotinib 400 mg twice daily and 0.7%,</p><p>12.0%, 18.0% and 22.3% for imatinib 400 mg once daily.</p><p>&nbsp;</p><p>The MMR rate at 12, 24, 36, 48, 60 and 72 months is presented in Table 7.</p><p>&nbsp;</p><p>Table 7 MMR rate</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nilotinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg twice daily n=282 (%)</p></td><td style="vertical-align:top"><p>Nilotinib 400 mg twice daily n=281 (%)</p></td><td style="vertical-align:top"><p>Imatinib 400 mg once daily n=283 (%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMRat 12 months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>44.31 (38.4; 50.3)</p></td><td style="vertical-align:top"><p>42.71 (36.8; 48.7)</p></td><td style="vertical-align:top"><p>22.3 (17.6; 27.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR at 24 months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>61.71 (55.8; 67.4)</p></td><td style="vertical-align:top"><p>59.11 (53.1; 64.9)</p></td><td style="vertical-align:top"><p>37.5 (31.8; 43.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR at 36 months</strong><strong>2</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>58.51 (52.5; 64.3)</p></td><td style="vertical-align:top"><p>57.31 (51.3; 63.2)</p></td><td style="vertical-align:top"><p>38.5 (32.8; 44.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR at 48 months</strong><strong>3</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>59.91 (54.0; 65.7)</p></td><td style="vertical-align:top"><p>55.2 (49.1; 61.1)</p></td><td style="vertical-align:top"><p>43.8 (38.0; 49.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR at 60 months</strong><strong>4</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>62.8 (56.8; 68.4)</p></td><td style="vertical-align:top"><p>61.2 (55.2; 66.9)</p></td><td style="vertical-align:top"><p>49.1 (43.2; 55.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR at 72 months</strong><strong>5</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>52.5 (46.5; 58.4)</p></td><td style="vertical-align:top"><p>57.7 (51.6; 63.5)</p></td><td style="vertical-align:top"><p>41.7 (35.9; 47.7)</p></td></tr></tbody></table><p>1 Cochran-Mantel-Haenszel (CMH) test p-value for response rate (vs. imatinib 400 mg) &lt;0.0001</p><p>&nbsp;</p><p>2 Only patients who were in MMR at a specific time point are included as responders for that time point. A total of 199 (35.2%) of all patients were not evaluable for MMR at 36 months (87 in the nilotinib 300 mg twice daily group and 112 in the imatinib group) due to missing/unevaluable PCR assessments (n=17), atypical transcripts at baseline (n=7), or discontinuation prior to the 36-month time point (n=175).</p><p>3 Only patients who were in MMR at a specific time point are included as responders for that time point. A total of 305 (36.1%) of all patients were not evaluable for MMR at 48 months (98 in the nilotinib 300 mg BID group, 88 in the nilotinib 400 mg BID group and 119 in the imatinib group) due to missing/unevaluable PCR assessments (n=18), atypical transcripts at baseline (n=8), or discontinuation prior to the 48-month time point (n=279).</p><p>4 Only patients who were in MMR at a specific time point are included as responders for that time point. A total of 322 (38.1%) of all patients were not evaluable for MMR at 60 months (99 in the nilotinib 300 mg twice daily group, 93 in the nilotinib 400 mg twice daily group and 130 in the imatinib group) due to missing/unevaluable PCR assessments (n=9), atypical transcripts at baseline (n=8) or discontinuation prior to the 60-month time point (n=305).</p><p>5 Only patients who were in MMR at a specific time point are included as responders for that time point. A total of 395 (46.7%) of all patients were not evaluable for MMR at 72 months (130 in the nilotinib 300 mg twice daily group, 110 in the nilotinib 400 mg twice daily group and 155 in the imatinib group) due to missing/unevaluable PCR assessments (n=25), atypical transcripts at baseline (n=8) or discontinuation prior to the 72-month time point (n=362).</p><p>&nbsp;</p><p>&nbsp;</p><p>MMR rates by different time points (including patients who achieved MMR at or before those time points as responders) are presented in the cumulative incidence of MMR (see Figure 1).</p><p>Figure 1 Cumulative incidence of MMR</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image2.jpeg" o:spid="_x0000_s1029" type="#_x0000_t75"
  alt="þÿ" style='position:absolute;margin-left:82.35pt;margin-top:16.35pt;
  width:448.85pt;height:270.5pt;z-index:3;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title="þÿ"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="599" height="361" alt="þÿ" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>For all Sokal risk groups, the MMR rates at all time points remained consistently higher in the two nilotinib groups than in the imatinib group.</p><p>In a retrospective analysis, 91% (234/258) of patients on nilotinib 300 mg twice daily achieved BCR-ABL levels &le;10% at 3 months of treatment compared to 67% (176/264) of patients on imatinib 400 mg once daily. Patients with BCR-ABL levels &le;10% at 3 months of treatment show a greater overall survival at 72 months compared to those who did not achieve this molecular response level (94.5% vs. 77.1% respectively [p=0.0005]).</p><p>Based on the Kaplan-Meier analysis of time to first MMR the probability of achieving MMR at different time points was higher for both nilotinib at 300 mg and 400 mg twice daily compared to imatinib 400 mg once daily (HR=2.17 and stratified log-rank p&lt;0.0001 between nilotinib 300 mg</p><p>&nbsp;</p><p>&nbsp;</p><p>twice daily and imatinib 400 mg once daily, HR=1.88 and stratified log-rank p&lt;0.0001 between nilotinib 400 mg twice daily and imatinib 400 mg once daily).</p><p>The proportion of patients who had a molecular response of &le;0.01% and &le;0.0032% by IS at different time points are presented in Table 8 and the proportion of patients who had a molecular response of &le;0.01% and &le;0.0032% by IS by different time points are presented in Figures 2 and</p><p>3. Molecular responses of &le;0.01% and &le;0.0032% by IS correspond to a &ge;4 log reduction and</p><p>&ge;4.5 log reduction, respectively, of BCR-ABL transcripts from a standardised baseline.</p><p>&nbsp;</p><p>Table 8 Proportions of patients who had molecular response of &le;0.01% (4 log reduction) and &le;0.0032% (4.5 log reduction)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Nilotinib</p><p>300 mg twice daily n=282</p><p>(%)</p></td><td colspan="2" style="vertical-align:top"><p>Nilotinib</p><p>400 mg twice daily n=281</p><p>(%)</p></td><td colspan="2" style="vertical-align:top"><p>Imatinib</p><p>400 mg once daily n=283</p><p>(%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&le;0.01%</strong></p></td><td style="vertical-align:top"><p><strong>&le;0.0032%</strong></p></td><td style="vertical-align:top"><p><strong>&le;0.01%</strong></p></td><td style="vertical-align:top"><p><strong>&le; 0.0032%</strong></p></td><td style="vertical-align:top"><p><strong>&le;0.01%</strong></p></td><td style="vertical-align:top"><p><strong>&le;0.0032%</strong></p></td></tr><tr><td style="vertical-align:top"><p>At 12 months</p></td><td style="vertical-align:top"><p>11.7</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>At 24 months</p></td><td style="vertical-align:top"><p>24.5</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>22.1</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>10.2</p></td><td style="vertical-align:top"><p>2.8</p></td></tr><tr><td style="vertical-align:top"><p>At 36 months</p></td><td style="vertical-align:top"><p>29.4</p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>23.8</p></td><td style="vertical-align:top"><p>12.1</p></td><td style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>8.1</p></td></tr><tr><td style="vertical-align:top"><p>At 48 months</p></td><td style="vertical-align:top"><p>33.0</p></td><td style="vertical-align:top"><p>16.3</p></td><td style="vertical-align:top"><p>29.9</p></td><td style="vertical-align:top"><p>17.1</p></td><td style="vertical-align:top"><p>19.8</p></td><td style="vertical-align:top"><p>10.2</p></td></tr><tr><td style="vertical-align:top"><p>At 60 months</p></td><td style="vertical-align:top"><p>47.9</p></td><td style="vertical-align:top"><p>32.3</p></td><td style="vertical-align:top"><p>43.4</p></td><td style="vertical-align:top"><p>29.5</p></td><td style="vertical-align:top"><p>31.1</p></td><td style="vertical-align:top"><p>19.8</p></td></tr><tr><td style="vertical-align:top"><p>At 72 months</p></td><td style="vertical-align:top"><p>44.3</p></td><td style="vertical-align:top"><p>31.2</p></td><td style="vertical-align:top"><p>45.2</p></td><td style="vertical-align:top"><p>28.8</p></td><td style="vertical-align:top"><p>27.2</p></td><td style="vertical-align:top"><p>18.0</p></td></tr></tbody></table><p><strong>Figure 2 Cumulative incidence of molecular response of &le;0.01% (4-log reduction)</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="image3.jpeg"
 o:spid="_x0000_i1025" type="#_x0000_t75" alt="þÿ" style='width:446.5pt;
 height:258.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg"
  o:title="þÿ"/>
</v:shape><![endif]--><img width="595" height="345" alt="þÿ" src="data:image/jpeg;base64,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" /></p><p><strong>&nbsp;</strong></p><p><strong>Figure 3 Cumulative incidence of molecular response of &le;0.0032% (4.5 log reduction)</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image4.jpeg" o:spid="_x0000_s1028" type="#_x0000_t75" alt="þÿ" style='position:absolute;
  margin-left:84.1pt;margin-top:14.15pt;width:424.5pt;height:247.25pt;
  z-index:4;visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg"
   o:title="þÿ"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="566" height="329" alt="þÿ" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>Based on Kaplan-Meier estimates of the duration of first MMR, the proportions of patients who were maintaining response for 72 months among patients who achieved MMR were 92.5% (95% CI: 88.6-96.4%) in the nilotinib 300 mg twice daily group, 92.2% (95% CI: 88.5-95.9%) in the</p><p>nilotinib 400 mg twice daily group and 88.0% (95% CI: 83.0-93.1%) in the imatinib 400 mg once daily group.</p><p>Complete cytogenetic response (CCyR) was defined as 0% Ph+ metaphases in the bone marrow based on a minimum of 20 metaphases evaluated. Best CCyR rate by 12 months (including patients who achieved CCyR at or before the 12 month time point as responders) was statistically higher for both nilotinib 300 mg and 400 mg twice daily compared to imatinib 400 mg once daily, see Table 9.</p><p>CCyR rate by 24 months (includes patients who achieved CCyR at or before the 24 month time point as responders) was statistically higher for both the nilotinib 300 mg twice daily and 400 mg twice daily groups compared to the imatinib 400 mg once daily group.</p><p>Table 9 Best CCyR rate</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nilotinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg twice daily n=282 (%)</p></td><td style="vertical-align:top"><p>Nilotinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 400&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg twice daily n=281 (%)</p></td><td style="vertical-align:top"><p>Imatinib 400 mg once daily n=283 (%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>By 12 months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>80.1 (75.0; 84.6)</p></td><td style="vertical-align:top"><p>77.9 (72.6; 82.6)</p></td><td style="vertical-align:top"><p>65.0 (59.2; 70.6)</p></td></tr><tr><td style="vertical-align:top"><p>No response</p></td><td style="vertical-align:top"><p>19.9</p></td><td style="vertical-align:top"><p>22.1</p></td><td style="vertical-align:top"><p>35.0</p></td></tr><tr><td style="vertical-align:top"><p>CMH test p-value for response rate (versus imatinib 400 mg once daily)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.0005</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>By 24 months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Response (95% CI)</p></td><td style="vertical-align:top"><p>86.9 (82.4; 90.6)</p></td><td style="vertical-align:top"><p>84.7 (79.9; 88.7)</p></td><td style="vertical-align:top"><p>77.0 (71.7; 81.8)</p></td></tr><tr><td style="vertical-align:top"><p>No response</p></td><td style="vertical-align:top"><p>13.1</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>23.0</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>CMH test p-value for response rate (versus imatinib 400 mg once daily)</p></td><td style="vertical-align:top"><p>0.0018</p></td><td style="vertical-align:top"><p>0.0160</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Based on Kaplan-Meier estimates, the proportions of patients who were maintaining response for</p><p>72 months among patients who achieved CCyR were 99.1% (95% CI: 97.9-100%) in the nilotinib 300 mg twice daily group, 98.7% (95% CI: 97.1-100%) in the nilotinib 400 mg twice daily group and 97.0% (95% CI: 94.7-99.4%) in the imatinib 400 mg once daily group.</p><p>Progression to accelerated phase (AP) or blast crisis (BC) on treatment is defined as the time from the date of randomisation to the first documented disease progression to accelerated phase or blast crisis or CML-related death. Progression to accelerated phase or blast crisis on treatment was observed in a total of 17 patients: 2 patients on nilotinib 300 mg twice daily, 3 patients on nilotinib 400 mg twice daily and 12 patients on imatinib 400 mg once daily. The estimated rates of patients free from progression to accelerated phase or blast crisis at 72 months were 99.3%, 98.7% and 95.2%, respectively (HR=0.1599 and stratified log-rank p=0.0059 between nilotinib</p><p>300 mg twice daily and imatinib once daily, HR=0.2457 and stratified log-rank p=0.0185 between nilotinib 400 mg twice daily and imatinib once daily). No new events of progression to AP/BC were reported on-treatment since the 2-year analysis.</p><p>Including clonal evolution as a criterion for progression, a total of 25 patients progressed to accelerated phase or blast crisis on treatment by the cut-off date (3 in the nilotinib 300 mg twice daily group, 5 in the nilotinib 400 mg twice daily group and 17 in the imatinib 400 mg once daily group). The estimated rates of patients free from progression to accelerated phase or blast crisis including clonal evolution at 72 months were 98.7%, 97.9% and 93.2%, respectively (HR=0.1626 and stratified log-rank p=0.0009 between nilotinib 300 mg twice daily and imatinib once daily, HR=0.2848 and stratified log-rank p=0.0085 between nilotinib 400 mg twice daily and imatinib once daily).</p><p>A total of 55 patients died during treatment or during the follow-up after discontinuation of treatment (21 in the nilotinib 300 mg twice daily group, 11 in the nilotinib 400 mg twice daily group and 23 in the imatinib 400 mg once daily group). Twenty-six (26) of these 55 deaths were</p><p>&nbsp;</p><p>&nbsp;</p><p>related to CML (6 in the nilotinib 300 mg twice daily group, 4 in the nilotinib 400 mg twice daily group and 16 in the imatinib 400 mg once daily group). The estimated rates of patients alive at 72 months were 91.6%, 95.8% and 91.4%, respectively (HR=0.8934 and stratified log-rank p=0.7085 between nilotinib 300 mg twice daily and imatinib, HR=0.4632 and stratified log-rank p=0.0314 between nilotinib 400 mg twice daily and imatinib). Considering only CML-related deaths as events, the estimated rates of overall survival at 72 months were 97.7%, 98.5% and 93.9%, respectively (HR=0.3694 and stratified log-rank p=0.0302 between nilotinib 300 mg twice daily and imatinib, HR=0.2433 and stratified log-rank p=0.0061 between nilotinib 400 mg twice daily and imatinib).</p><p><em><u>Clinical studies in imatinib-resistant or intolerant CML in chronic phase and accelerated phase</u></em></p><p><em>&nbsp;</em></p><p>An open-label, uncontrolled, multicentre Phase II study was conducted to determine the efficacy of nilotinib in adult patients with imatinib resistant or intolerant CML with separate treatment arms for chronic and accelerated phase disease. Efficacy was based on 321 CP patients and 137 AP patients enrolled. Median duration of treatment was 561 days for CP patients and 264 days for AP patients (see Table 10). Nilotinib was administered on a continuous basis (twice daily 2 hours after a meal and with no food for at least one hour after administration) unless there was evidence of inadequate response or disease progression. The dose was 400 mg twice daily and dose escalation to 600 mg twice daily was allowed.</p><p>Table 10 Duration of exposure with nilotinib</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chronic phase n=321</p></td><td style="vertical-align:top"><p>Accelerated phase n=137</p></td></tr><tr><td style="vertical-align:top"><p>Median duration of therapy in days (25th-75th percentiles)</p></td><td style="vertical-align:top"><p>561</p><p>(196-852)</p></td><td style="vertical-align:top"><p>264</p><p>(115-595)</p></td></tr></tbody></table><p>Resistance to imatinib included failure to achieve a complete haematological response (by 3 months), cytogenetic response (by 6 months) or major cytogenetic response (by 12 months) or progression of disease after a previous cytogenetic or haematological response. Imatinib</p><p>&nbsp;</p><p>&nbsp;</p><p>intolerance included patients who discontinued imatinib because of toxicity and were not in major cytogenetic response at time of study entry.</p><p>Overall, 73% of patients were imatinib-resistant, while 27% were imatinib-intolerant. The majority of patients had a long history of CML that included extensive prior treatment with other antineoplastic agents, including imatinib, hydroxyurea, interferon, and some had even failed organ transplant (Table 11). The median highest prior imatinib dose had been 600 mg/day. The highest prior imatinib dose was &ge;600 mg/day in 74% of all patients, with 40% of patients receiving imatinib doses &ge;800 mg/day.</p><p>Table 11 CML disease history characteristics</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chronic phase (n=321)</p></td><td style="vertical-align:top"><p>Accelerated phase (n=137)*</p></td></tr><tr><td style="vertical-align:top"><p>Median time since diagnosis in months (range)</p></td><td style="vertical-align:top"><p>58</p><p>(5&ndash;275)</p></td><td style="vertical-align:top"><p>71</p><p>(2&ndash;298)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Resistant</p></td><td style="vertical-align:top"><p>226 (70%)</p></td><td style="vertical-align:top"><p>109 (80%)</p></td></tr><tr><td style="vertical-align:top"><p>Intolerant without MCyR</p></td><td style="vertical-align:top"><p>95 (30%)</p></td><td style="vertical-align:top"><p>27 (20%)</p></td></tr><tr><td style="vertical-align:top"><p>Median time of imatinib treatment in days</p></td><td style="vertical-align:top"><p>975</p></td><td style="vertical-align:top"><p>857</p></td></tr><tr><td style="vertical-align:top"><p>(25th-75th percentiles)</p></td><td style="vertical-align:top"><p>(519-1,488)</p></td><td style="vertical-align:top"><p>(424-1,497)</p></td></tr><tr><td style="vertical-align:top"><p>Prior hydroxyurea</p></td><td style="vertical-align:top"><p>83%</p></td><td style="vertical-align:top"><p>91%</p></td></tr><tr><td style="vertical-align:top"><p>Prior interferon</p></td><td style="vertical-align:top"><p>58%</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>Prior bone marrow transplant</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Missing information on imatinib-resistant/intolerant status for one patient.</p></td></tr></tbody></table><p>The primary endpoint in the CP patients was major cytogenetic response (MCyR), defined as elimination (CCyR, complete cytogenetic response) or significant reduction to &lt;35% Ph+ metaphases (partial cytogenetic response) of Ph+ haematopoietic cells. Complete haematological response (CHR) in CP patients was evaluated as a secondary endpoint. The primary endpoint in</p><p>&nbsp;</p><p>&nbsp;</p><p>the AP patients was overall confirmed haematological response (HR), defined as either a complete haematological response, no evidence of leukaemia or return to chronic phase.</p><p><em>Chronic phase</em></p><p><em>&nbsp;</em></p><p>The MCyR rate in 321 CP patients was 51%. Most responders achieved their MCyR rapidly within 3 months (median 2.8 months) of starting nilotinib treatment and these were sustained. The median time to achieve CCyR was just past 3 months (median 3.4 months). Of the patients who achieved MCyR, 77% (95% CI: 70% - 84%) were maintaining response at 24 months. Median duration of MCyR has not been reached. Of the patients who achieved CCyR, 85% (95% CI: 78% - 93%) were maintaining response at 24 months. Median duration of CCyR has not been reached. Patients with a CHR at baseline achieved a MCyR faster (1.9 versus 2.8 months). Of CP patients without a baseline CHR, 70% achieved a CHR, median time to CHR was 1 month and median duration of CHR was 32.8 months. The estimated 24-month overall survival rate in CML-CP patients was 87%.</p><p><em>Accelerated phase</em></p><p><em>&nbsp;</em></p><p>The overall confirmed HR rate in 137 AP patients was 50%. Most responders achieved a HR early with nilotinib treatment (median 1.0 months) and these have been durable (median duration of confirmed HR was 24.2 months). Of the patients who achieved HR, 53% (95% CI: 39% - 67%) were maintaining response at 24 months. MCyR rate was 30% with a median time to response of 2.8 months. Of the patients who achieved MCyR, 63% (95% CI: 45% - 80%) were maintaining response at 24 months. Median duration of MCyR was 32.7 months. The estimated 24-month overall survival rate in CML-AP patients was 70%.</p><p>The rates of response for the two treatment arms are reported in Table 12.</p><p>&nbsp;</p><p>Table 12 Response in CML</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>(Best response rate)</p></td><td colspan="3" style="vertical-align:top"><p><strong>Chronic phase</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Accelerated phase</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Intolerant</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p></td><td style="vertical-align:top"><p><strong>Intolerant</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td><td style="vertical-align:top"><p><strong>Total*</strong></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>(n=95)</strong></p></td><td style="vertical-align:top"><p><strong>(n=226)</strong></p></td><td style="vertical-align:top"><p><strong>(n=321)</strong></p></td><td style="vertical-align:top"><p><strong>(n=27)</strong></p></td><td style="vertical-align:top"><p><strong>(n=109)</strong></p></td><td style="vertical-align:top"><p><strong>(n=137)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Haematological Response (%)</p></td></tr><tr><td style="vertical-align:top"><p>Overall (95%CI)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>48 (29-68)</p></td><td style="vertical-align:top"><p>51 (42-61)</p></td><td style="vertical-align:top"><p>50 (42-59)</p></td></tr><tr><td style="vertical-align:top"><p>Complete</p></td><td style="vertical-align:top"><p>87 (74-94)</p></td><td style="vertical-align:top"><p>65 (56-72)</p></td><td style="vertical-align:top"><p>701 (63-76)</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>30</p></td></tr><tr><td style="vertical-align:top"><p>NEL</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Return to CP</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Cytogenetic Response (%)</p></td></tr><tr><td style="vertical-align:top"><p>Major (95%CI)</p></td><td style="vertical-align:top"><p>57 (46-67)</p></td><td style="vertical-align:top"><p>49 (42-56)</p></td><td style="vertical-align:top"><p>51 (46-57)</p></td><td style="vertical-align:top"><p>33 (17-54)</p></td><td style="vertical-align:top"><p>29 (21-39)</p></td><td style="vertical-align:top"><p>30 (22-38)</p></td></tr><tr><td style="vertical-align:top"><p>Complete</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>Partial</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td></tr></tbody></table><p>NEL = no evidence of leukaemia/marrow response</p><p>&nbsp;</p><p>1 114 CP patients had a CHR at baseline and were therefore not assessable for complete haematological response</p><p>* Missing information on imatinib-resistant/intolerant status for one patient.</p><p>&nbsp;</p><p>Efficacy data in patients with CML-BC are not yet available. Separate treatment arms were also included in the Phase II study to investigate Nilotinib in a group of CP and AP patients who had been extensively pre-treated with multiple therapies including a tyrosine kinase inhibitor agent in addition to imatinib. Of these patients 30/36 (83%) were treatment resistant not intolerant. In 22 CP patients evaluated for efficacy nilotinib induced a 32% MCyR rate and a 50% CHR rate. In 11 AP patients, evaluated for efficacy, treatment induced a 36% overall HR rate.</p><p>After imatinib failure, 24 different BCR-ABL mutations were noted in 42% of chronic phase and 54% of accelerated phase CML patients who were evaluated for mutations. Nilotinib demonstrated efficacy in patients harboring a variety of BCR-ABL mutations associated with imatinib resistance, except T315I.</p><p><em><u>Treatment discontinuation in adult Ph+ CML patients in chronic phase who have been treated</u></em><em> <u>with nilotinib as first-line therapy and who have achieved a sustained deep molecular response</u></em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>In an open-label, single-arm study, 215 adult patients with Ph+ CML in chronic phase treated with nilotinib in first-line for &ge;2 years who achieved MR4.5 as measured with the MolecularMD MRDx BCR-ABL test were enrolled to continue nilotinib treatment for additional 52 weeks (nilotinib consolidation phase). 190 of 215 patients (88.4%) entered the TFR phase after achieving a sustained deep molecular response during the consolidation phase, defined by the following criteria:</p><p>-&nbsp;&nbsp; the 4 last quarterly assessments (taken every 12 weeks) were at least MR4.0 (BCR-ABL/ABL</p><p>&le;0.01% IS), and maintained for one year</p><p>&nbsp;</p><p>-&nbsp; the last assessment being MR4.5 (BCR-ABL/ABL &le;0.0032% IS)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; no more than two assessments falling between MR4.0 and MR4.5 (0.0032% IS &lt; BCR-</p><p>ABL/ABL &le;0.01% IS).</p><p>&nbsp;</p><p>The primary endpoint was the percentage of patients in MMR at 48 weeks after starting the TFR phase (considering any patient who required re-initiation of treatment as non-responder).</p><p>Table 13 Treatment-free remission after nilotinib first-line treatment</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Patients entered TFR phase</p></td><td colspan="2" style="vertical-align:top"><p>190</p></td></tr><tr><td style="vertical-align:top"><p>weeks after starting TFR phase</p></td><td style="vertical-align:top"><p>48 weeks</p></td><td style="vertical-align:top"><p>264 weeks</p></td></tr><tr><td style="vertical-align:top"><p>patients remaining in MMR or better</p></td><td style="vertical-align:top"><p>98 (51.6%, [95% CI: 44.2,</p><p>58.9])</p></td><td style="vertical-align:top"><p>79[2] (41.6%, 95% CI: 34.5,</p><p>48.9)</p></td></tr><tr><td style="vertical-align:top"><p>Patients discontinued TFR phase</p></td><td style="vertical-align:top"><p>93 [1]</p></td><td style="vertical-align:top"><p>109</p></td></tr><tr><td style="vertical-align:top"><p>due to loss of MMR</p></td><td style="vertical-align:top"><p>88 (46.3%)</p></td><td style="vertical-align:top"><p>94 (49.5%)</p></td></tr><tr><td style="vertical-align:top"><p>due to other reasons</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Patients restarted treatment after loss of MMR</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>91</p></td></tr><tr><td style="vertical-align:top"><p>regaining MMR</p></td><td style="vertical-align:top"><p>85 (98.8%)</p></td><td style="vertical-align:top"><p>90 (98.9%)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>regaining MR4.5</p></td><td style="vertical-align:top"><p>76 (88.4%)</p></td><td style="vertical-align:top"><p>84 (92,3%)</p></td></tr></tbody></table><p>[1]&nbsp; One patient did not lose MMR by week 48 but discontinued TFR phase.</p><p>&nbsp;</p><p>[2]&nbsp;&nbsp; For 2 patients, PCR assessment was not available at week 264 therefore their response was not considered for the week 264 data cut-off analysis.</p><p>The time by which 50% of all retreated patients regained MMR and MR4.5 was 7 and 12.9 weeks, respectively. The cumulative rate of MMR regained at 24 weeks after treatment re- initiation was 97.8% (89/91 patients) and MR4.5 regained at 48 weeks was 91.2% (83/91 patients).</p><p>The Kaplan-Meier estimate of median treatment-free survival (TFS) was 120.1 weeks (95% CI: 36.9, not estimable [NE]) (Figure 4); 91 of 190 patients (47.9%) did not have a TFS event.</p><p>Figure 4 Kaplan-Meier estimate of treatment-free survival after start of TFR (full analysis set)</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image5.png" o:spid="_x0000_s1027" type="#_x0000_t75" alt="þÿ" style='position:absolute;
  margin-left:83.35pt;margin-top:12.15pt;width:419.25pt;height:213.6pt;
  z-index:5;visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
   o:title="þÿ"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="559" height="285" alt="þÿ" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><em><u>Treatment discontinuation in adult CML patients in chronic phase who have achieved a</u></em><em> <u>sustained deep molecular response on nilotinib treatment following prior imatinib therapy</u></em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>In an open-label, single-arm study, 163 adult patients with Ph+ CML in chronic phase taking tyrosine kinase inhibitors (TKIs) for &ge;3 years (imatinib as initial TKI therapy for more than 4 weeks without documented MR4.5 on imatinib at the time of switch to nilotinib, then switched to nilotinib for at least two years), and who achieved MR4.5 on nilotinib treatment as measured with the MolecularMD MRDx BCR-ABL test were enrolled to continue nilotinib treatment for additional 52 weeks (nilotinib consolidation phase). 126 of 163 patients (77.3%) entered the TFR phase after achieving a sustained deep molecular response during the consolidation phase, defined by the following criterion:</p><p>-&nbsp;&nbsp; The 4 last quarterly assessments (taken every 12 weeks) showed no confirmed loss of MR4.5 (BCR-ABL/ABL &le;0.0032% IS) during one year.</p><p>The primary endpoint was the proportion of patients without confirmed loss of MR4.0 or loss of MMR within 48 weeks following treatment discontinuation.</p><p>Table 14 Treatment-free remission after nilotinib treatment following prior imatinib therapy</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Patients entered TFR phase</p></td><td colspan="2" style="vertical-align:top"><p>126</p></td></tr><tr><td style="vertical-align:top"><p>weeks after starting TFR phase</p></td><td style="vertical-align:top"><p>48 weeks</p></td><td style="vertical-align:top"><p>264 weeks</p></td></tr><tr><td style="vertical-align:top"><p>patients remaining in MMR, no confirmed loss of MR4.0, and no re-initiation of nilotinib</p></td><td style="vertical-align:top"><p>73 (57.9%, [95% CI: 48.8,</p><p>66.7])</p></td><td style="vertical-align:top"><p>54 (42.9% [54/126, 95% CI:</p><p>34.1, 52.0])</p></td></tr><tr><td style="vertical-align:top"><p>Patients discontinued TFR Phase</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>74 [1]</p></td></tr><tr><td style="vertical-align:top"><p>due to confirmed loss of MR4.0 or loss of MMR</p></td><td style="vertical-align:top"><p>53 (42.1%)</p></td><td style="vertical-align:top"><p>61 (82.4%)</p></td></tr><tr><td style="vertical-align:top"><p>due to other reasons</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>Patients restarted treatment after loss of MMR or confirmed loss of MR4.0</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>59</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>regaining MR4.0</p></td><td style="vertical-align:top"><p>48 (94.1%)</p></td><td style="vertical-align:top"><p>56 (94.9%)</p></td></tr><tr><td style="vertical-align:top"><p>regaining MR4.5</p></td><td style="vertical-align:top"><p>47 (92.2%)</p></td><td style="vertical-align:top"><p>54 (91.5%)</p></td></tr></tbody></table><p>[1] two patients had MMR (PCR assessment) at 264 weeks but were discontinued later and had no further PCR assessment.</p><p>The Kaplan-Meier estimated median time on nilotinib to regain MR4.0 and MR4.5 was 11.1 weeks (95% CI:8.1, 12.1) and 13.1 weeks (95% CI:12.0, 15.9), respectively. The cumulative rate of MR4 and MR4.5 regained by 48 weeks after treatment re-initiation was 94.9% (56/59 patients) and 91.5% (54/59 patients), respectively.</p><p>The median TFS Kaplan-Meier estimate is 224 weeks (95% CI: 39.9, NE) (Figure 5); 63 of 126 patients (50.0%) did not have a TFS event.</p><p>Figure 5 Kaplan-Meier estimate of treatment-free survival after start of TFR (full analysis set)</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image6.png" o:spid="_x0000_s1026" type="#_x0000_t75" alt="þÿ" style='position:absolute;
  margin-left:90.85pt;margin-top:8.65pt;width:426.25pt;height:221.05pt;
  z-index:6;visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif"
   o:title="þÿ"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="568" height="295" alt="þÿ" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>&nbsp;</p><p>The safety and efficacy of nilotinib in paediatric patients with Ph+ CML in chronic phase have been investigated in two studies. A total of 69 paediatric patients (from 2 to &lt;18 years of age) with either newly diagnosed Ph+ CML in chronic phase (n=25) or imatinib/dasatinib resistant or imatinib-intolerant Ph+ CML in chronic phase (n=44) received nilotinib treatment at a dose of 230 mg/m2 twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg).</p><p>In the pooled CML patient population, the median actual dose intensity was 435.5 mg/m2/day (range: 149 to 517 mg/m2/day), and the median relative dose intensity was 94.7% (range: 32 to 112%). Forty patients (58.0%) had relative dose intensity superior to 90%. The median time on treatment with nilotinib was 13.80 months (range: 0.7-30.9 months).</p><p>In the resistant or intolerant CML patients, the major molecular response (MMR; BCR- ABL/ABL &le;0.1% IS) rate was 40.9% (95% CI: 26.3, 56.8) at 12 cycles, with 18 patients being in MMR. In the newly diagnosed CML patients, the MMR rate was 60.0% (95% CI: 38.7, 78.9) at</p><p>12 cycles, with 15 patients achieving MMR. In resistant or intolerant CML patients, the cumulative MMR rate was 47.7% by cycle 12. In newly diagnosed CML patients, the cumulative MMR rate was 64.0% by cycle 12.</p><p>Among the 21 resistant or intolerant CML patients who were in MMR at any time on treatment, the median time to first MMR was 2.76 months (95% CI: 0.03, 5.55). For the 17 newly diagnosed CML patients who achieved MMR, the median time to first MMR was 5.55 months (95% CI: 5.52, 5.75).</p><p>Among resistant or intolerant CML patients, the percentage of patients who achieved BCR- ABL/ABL &le;0.01% IS (MR4.0) by the cut-off date was 11.4%, while 4.5% of the patients achieved BCR-ABL/ABL &le;0.0032% IS (MR4.5). Among newly diagnosed patients, the percentage of patients who achieved MR4.0 was 32%, while 28.0% achieved MR4.5.</p><p>None of the 21 resistant or intolerant CML patients who were in MMR on treatment had confirmed loss of MMR. Among the 17 newly diagnosed CML patients who achieved MMR,</p><p>&nbsp;</p><p>&nbsp;</p><p>one patient had confirmed loss of MMR (the patient lost CHR due to an increase in basophil count, however did not progress to AP/BC).</p><p>One resistant or intolerant CML patient progressed to AP/BC after about 10 months on treatment.</p><p>No deaths were reported on treatment or after treatment discontinuation in both studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Peak concentrations of nilotinib are reached 3 hours after oral administration. Nilotinib absorption following oral administration was approximately 30%. The absolute bioavailability of nilotinib has not been determined. As compared to an oral drink solution (pH of 1.2 to 1.3), relative bioavailability of nilotinib capsule is approximately 50%. In healthy volunteers, Cmax and area under the serum concentration-time curve (AUC) of nilotinib are increased by 112% and 82%, respectively, compared to fasting conditions when Nilo is given with food. Administration of Nilo 30 minutes or 2 hours after food increased bioavailability of nilotinib by 29% or 15%, respectively (see sections 4.2, 4.4 and 4.5).</p><p>Nilotinib absorption (relative bioavailability) might be reduced by approximately 48% and 22% in patients with total gastrectomy and partial gastrectomy, respectively.</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The blood-to-plasma ratio of nilotinib is 0.71. Plasma protein binding is approximately 98% on the basis of <em>in vitro </em>experiments.</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Main metabolic pathways identified in healthy subjects are oxidation and hydroxylation. Nilotinib is the main circulating component in the serum. None of the metabolites contribute significantly to the pharmacological activity of nilotinib. Nilotinib is primarily metabolised by CYP3A4, with possible minor contribution from CYP2C8.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>After a single dose of radiolabelled nilotinib in healthy subjects, more than 90% of the dose was eliminated within 7 days, mainly in faeces (94% of the dose). Unchanged nilotinib accounted for 69% of the dose.</p><p>The apparent elimination half-life estimated from the multiple-dose pharmacokinetics with daily dosing was approximately 17 hours. Inter-patient variability in nilotinib pharmacokinetics was moderate to high.</p><p><u>Linearity/non<strong>-</strong>linearity</u></p><p>&nbsp;</p><p>Steady-state nilotinib exposure was dose-dependent, with less than dose-proportional increases&nbsp; in systemic exposure at dose levels higher than 400 mg given as once-daily dosing. Daily systemic exposure to nilotinib with 400 mg twice-daily dosing at steady state was 35% higher than with 800 mg once-daily dosing. Systemic exposure (AUC) of nilotinib at steady state at a dose level of 400 mg twice daily was approximately 13.4% higher than at a dose level of 300 mg twice daily. The average nilotinib trough and peak concentrations over 12 months were approximately 15.7% and 14.8% higher following 400 mg twice-daily dosing compared to 300 mg twice daily. There was no relevant increase in exposure to nilotinib when the dose was increased from 400 mg twice daily to 600 mg twice daily.</p><p>Steady-state conditions were essentially achieved by day 8. An increase in serum exposure to nilotinib between the first dose and steady state was approximately 2-fold for daily dosing and 3.8-fold for twice-daily dosing.</p><p><u>Bioavailability/bioequivalence studies</u></p><p>&nbsp;</p><p>Single-dose administration of 400 mg nilotinib, using 2 hard capsules of 200 mg whereby the content of each hard capsule was dispersed in one teaspoon of apple sauce, was shown to be bioequivalent with a single-dose administration of 2 intact hard capsules of 200 mg.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Following administration of nilotinib in paediatric patients at 230 mg/m2 twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg), steady-state exposure and clearance of nilotinib were found to be similar (within 2-fold) to adult patients treated with 400 mg twice daily. The pharmacokinetic exposure of nilotinib following a single or multiple doses appeared to be comparable between paediatric patients from 2 years to &lt;10 years and from &ge;10 years to &lt;18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nilotinib has been evaluated in safety pharmacology, repeated-dose toxicity, genotoxicity, reproductive toxicity, phototoxicity and carcinogenicity (rats and mice) studies.</p><p><u>Safety pharmacology studies</u></p><p>&nbsp;</p><p>Nilotinib did not have effects on CNS or respiratory functions. <em>In vitro </em>cardiac safety studies demonstrated a preclinical signal for QT prolongation, based upon block of hERG currents and prolongation of the action potential duration in isolated rabbit hearts by nilotinib. No effects were seen in ECG measurements in dogs or monkeys treated for up to 39 weeks or in a special telemetry study in dogs.</p><p><u>Repeated-dose toxicity studies</u></p><p>&nbsp;</p><p>Repeated-dose toxicity studies in dogs of up to 4 weeks&#39; duration and in cynomolgus monkeys of up to 9 months&#39; duration revealed the liver as the primary target organ of toxicity of nilotinib. Alterations included increased alanine aminotransferase and alkaline phosphatase activity and histopathology findings (mainly sinusoidal cell or Kupffer cell hyperplasia/hypertrophy,&nbsp; bile duct hyperplasia and periportal fibrosis). In general the changes in clinical chemistry were fully reversible after a four-week recovery period and the histological alterations showed partial reversibility. Exposures at the lowest dose levels at which the liver effects were seen were lower than the exposure in humans at a dose of 800 mg/day. Only minor liver alterations were seen in mice or rats treated for up to 26 weeks. Mainly reversible increases in cholesterol levels were seen in rats, dogs and monkeys.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Genotoxicity studies</u></p><p>&nbsp;</p><p>Genotoxicity studies in bacterial <em>in vitro </em>systems and in mammalian <em>in vitro </em>and <em>in vivo </em>systems with and without metabolic activation did not reveal any evidence for a mutagenic potential of nilotinib.</p><p><u>Carcinogenicity studies</u></p><p>&nbsp;</p><p>In the 2-year rat carcinogenicity study, the major target organ for non-neoplastic lesions was the uterus (dilatation, vascular ectasia, endothelial cell hyperplasia, inflammation and/or epithelial hyperplasia). There was no evidence of carcinogenicity upon administration of nilotinib at 5, 15 and 40 mg/kg/day. Exposures (in terms of AUC) at the highest dose level represented approximately 2x to 3x human daily steady-state exposure (based on AUC) to nilotinib at the dose of 800 mg/day.</p><p>In the 26-week Tg.rasH2 mouse carcinogenicity study, in which nilotinib was administered at 30, 100 and 300 mg/kg/day, skin papillomas/carcinomas were detected at 300 mg/kg, representing approximately 30 to 40 times (based on AUC) the human exposure at the maximum approved dose of 800 mg/day (administered as 400 mg twice daily). The No-Observed-Effect-Level for the skin neoplastic lesions was 100 mg/kg/day, representing approximately 10 to 20 times the human exposure at the maximum approved dose of 800 mg/day (administered as 400 mg twice daily). The major target organs for non-neoplastic lesions were the skin (epidermal hyperplasia), the growing teeth (degeneration/atrophy of the enamel organ of upper incisors and inflammation of the gingiva/odontogenic epithelium of incisors) and the thymus (increased incidence and/or severity of decreased lymphocytes).</p><p><u>Reproductive toxicity and fertility studies</u></p><p>&nbsp;</p><p>Nilotinib did not induce teratogenicity, but did show embryo- and foetotoxicity at doses that also showed maternal toxicity. Increased post-implantation loss was observed in both the fertility study, which involved treatment of both males and females, and the embryotoxicity study, which involved treatment of females. Embryo-lethality and foetal effects (mainly decreased foetal</p><p>&nbsp;</p><p>&nbsp;</p><p>weights, premature fusion of the facial bones (fused maxilla/zygomatic) visceral and skeletal variations) in rats and increased resorption of foetuses and skeletal variations in rabbits were present in the embryotoxicity studies. In a pre- and postnatal development study in rats, maternal exposure to nilotinib caused reduced pup body weight with associated changes in physical development parameters as well as reduced mating and fertility indices in the offspring. Exposure to nilotinib in females at No-Observed-Adverse-Effect-Levels was generally less or equal to that in humans at 800 mg/day.</p><p>No effects on sperm count/motility or on fertility were noted in male and female rats up to the highest tested dose, approximately 5 times the recommended dosage for humans.</p><p><u>Juvenile animal studies</u></p><p>&nbsp;</p><p>In a juvenile development study, nilotinib was administered via oral gavage to juvenile rats from the first week post partum through young adult (day 70 post partum) at doses of 2, 6 and 20 mg/kg/day. Besides standard study parameters, evaluations of developmental landmarks, CNS effects, mating and fertility were performed. Based on a reduction in body weight in both genders and a delayed preputial separation in males (which may be associated with the reduction in weight), the No-Observed-Effect-Level in juvenile rats was considered to be 6 mg/kg/day. The juvenile animals did not exert increased sensitivity to nilotinib relative to adults. In addition, the toxicity profile in juvenile rats was comparable to that observed in adult rats.</p><p><u>Phototoxicity studies</u></p><p>&nbsp;</p><p>Nilotinib was shown to absorb light in the UV-B and UV-A range, is distributed into the skin and showed a phototoxic potential <em>in vitro</em>, but no effects have been observed <em>in vivo</em>. Therefore the risk that nilotinib causes photosensitisation in patients is considered very low.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>colloidal silicon dioxide, dibasic calcium phosphate dihydrate, gelatin, iron oxide yellow, magnesium stearate, povidone, sodium lauryl sulfate and titanium dioxide.</p><p>The imprinting ink contains shellac, propylene glycol, strong ammonia solution and iron oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life is 2 Years.
In-use shelf-life is 1 Month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>28&rsquo;s Count HDPE container</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441, Saudi Arabia, Tel: +966 11 477 2215
Manufacture: Hetero Labs Limited Unit V, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July, 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>